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Mahmoud S Alghamri Ph.D. Biomedical Sciences Ph.D. Program. Wright State 
University, 2016. Novel therapeutic approach for regulating the susceptibility of epithelia 
to adenovirus infection. 
Human Adenoviruses (AdVs) are etiologic agents for respiratory tract, digestive 
tract, heart, and eye infections. Although most AdV infections are self-resolving, some 
infections progress to acute respiratory disease with up to 50% mortality, particularly in 
immunosuppressed people. Except for vaccines for serotypes, 4 and 7, serotypes that are 
prevalent in the military, no vaccines or therapeutics that specifically prevent or treat 
AdV infection exist. On the other hand, AdV remains the most common vector system 
used in gene therapy clinical trials worldwide and several AdV vectors show promise in 
phase III clinical trials.  
The majority of AdVs use the coxsackievirus and adenovirus receptor (CAR) as a 
primary receptor. We have characterized an alternatively spliced eight-exon containing 
isoform (CAREx8) that localizes at the apical surface of epithelial cells and is responsible 
for the initiation of apical AdV infection. A cellular scaffold protein named Membrane 
Associated Guanylate Kinase, WW and PDZ Domain Containing 1 (MAGI-1) directly 
interacts with and alternatively regulates CAREx8 through the C-terminal PDZ-binding 
domain. The alternative regulation is due to the interaction with two different domains, 
namely PDZ1 and PDZ3, within the same molecule (MAGI-1). I hypothesized that cell 
permeable peptides that target the interaction between MAGI-1 PDZ1 domain and 
CAREx8 (TAT-PDZ1) would be able to decrease CAREx8 protein levels and prevent AdV 
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infection. On the other hand, peptides that target the interaction between MAGI-1 PDZ3 
domain and CAREx8 (TAT-PDZ3) would be able to increase CAREx8 and enhance AdV 
mediated gene therapy. Decoy peptides that target the assigned domain were synthesized 
and conjugated to TAT cell permeable peptide to facilitate peptide entry (TAT-PDZ1; 
TAT-NET1, TAT-E6) or (TAT-PDZ3; TAT-CAREx8-9c, TAT-ESAM). Peptide entry into 
the polarized epithelia was confirmed by mass spectroscopy and fluorescence 
microscopy. Treatment with TAT-PDZ1 peptides decreased the cellular levels of CAREx8 
and suppressed AdV transduction in MDCK, human airway epithelia (HAE), as well as 
epithelia from cotton rats, an animal model of AdV pathogenicity. To determine the 
mechanism of peptide action, CAREx8 localization was tracked by immunofluorescence. 
Interestingly, TAT-PDZ1 caused nuclear translocation of CAREx8 C-term domain, an 
effect that was reversed by ADAM17 inhibitor (TIMP3) and γ-secretase inhibitor (Comp 
E), implicating the regulated intramembrane proteolysis (RIP) pathway. 
Immunoprecipitation and direct ligand binding assays showed that ADAM17 interacts 
specifically with MAGI-1 PDZ2 domain, suggesting that TAT-PDZ1 peptides caused 
CAREx8 degradation by enhancing the proximity of the substrate (CAREx8) and enzyme 
(ADAM17). Finally, ADAM17 caused CAREx8 extracellular domain (ECD) shedding that 
was able to significantly decrease AdV-GFP transduction, indicating a second protective 
role against AdV entry by the shed ECD of CAREx8. By contrast, TAT-PDZ3 peptides 
increased the levels of CAREx8 and significantly increased AdV entry and transduction in 
MDCK, HAE, and cotton rat epithelia. Upon TAT-PDZ3 peptide administration, CAREx8 
was localized in vesicular pattern compartments distinct from MAGI-1 and spread 
throughout the apical trafficking pathway and at the apical surface of the epithelium. 
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Investigation of the trafficking pathway of CAREx8 using Rabs reveal the possibility of 
CAREx8 is residing within the recycling Endosomal-Golgi pathway. Neither TAT-PDZ1 
nor TAT-PDZ3 binding peptides altered epithelium formation, as measured by 
transepithelial resistance (TER) as well as dextran permeability across the epithelia, 
indicating the safety of the peptides on epithelial integrity. Moreover, intranasal 
administration of TAT-PDZ3 peptides increased AdV transduction by 300-500% while 
TAT-PDZ1 peptides decreased AdV transduction by 80-95% after intranasal 
administration in mice demonstrating in vivo activity. Taken together, these results 
validate a potential therapeutic approach of TAT-PDZ1 that can be used as a prophylactic 
agent to protect susceptible populations from AdV infections or the TAT-PDZ3 which 
can enhance adenovirus transduction and offer the potential to increase the efficacy of 
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Adenovirus (AdV) gained its name due to first being isolated from contaminated 
“adenoid” cells where it caused cell deformation (1). At the same time, another group 
discovered that it was the agent that was responsible for causing the common cold in 
military recruits (2). Soon after, the two microorganisms were recognized as the same 
virus (3) and both groups agreed on the common name as “adenovirus” based on the cell 
type from which it was first isolated. 
The non-enveloped capsid of adenoviruses is approximately 90-100 nanometers 
in size and icosahedral in structure. The predominant proteins in the structure of AdV are: 
1) The hexon base trimeric structure with more than 240 trimeric structures distributed 
equally over the twenty faces of AdV; 2) The penton base proteins distributed evenly to 
the 12 vertices of the capsid structure and join it with 3) the fiber knobs that project out of 
the icosahedral architecture (Figure 1). The fiber knobs have a crucial role because they 
are the first component of the AdV that interact with host cells. The AdV core structure 
contains a 35-40 kb double stranded DNA structure, which enables AdV to deliver a 
large amount of DNA into the host cell.  
Human AdV are classified into more than 57 serotypes, grouped into 7 species 
(A-G, Table 1). Most species (all except species B) use the Coxsackie and Adenovirus 
receptor (CAR) as their primary receptor. AdV is a serious etiologic human pathogen for 
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respiratory tract, digestive tract, heart, and eye infection, and can progress to acute 
respiratory distress syndrome (ARDS) and disseminated disease, with up to 50% 






Figure 1. Model structure of the human adenovirus (AdV). 
The penton base protein and hexon are within the core structure that package the 
double stranded DNA. The fiber knobs are trimeric protein structure that radiate out 
from the core structure and facilitate the AdV binding and entry into the host cell. 




Depending on serotype, AdV can also cause gastroenteritis with prolonged fecal 
shedding, or keratoconjunctivitis that can lead to blindness. In highly susceptible, 
immunosuppressed populations, such as in the transplant setting, AdV infections can be 
lethal. AdV are easily transmitted by airborne droplets from the infected individual to 
another, and it can survive in extreme conditions of low humidity and high temperature 
(8, 9). Due to its stability and ease of spread, many cases of AdV outbreaks have been 
reported (10-13). Epidemic AdV outbreaks occur in closed or crowded communities, 
particularly among children and military recruits (4, 14). Such characteristics render AdV 
as a highly virulent and opportunistic microorganism and mandate immediate invention 
for novel therapeutics. Unfortunately, no therapeutics that specifically treat or prevent 





Table 1. Classification of Human AdV serotype 
Species Serotype Site of infection Receptor (s) 
A 12, 18, 31 Gastrointestinal tract CAR 
B 
3, 7, 11, 14, 16, 21, 









8, 9, 10, 13, 15, 17, 
19, 20, 22-30, 32, 
33, 36-39, 42-49, 




E 4 Respiratory tract CAR 
F 40, 41 Gastrointestinal tract CAR 
G 52   
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Current vaccination and therapeutic strategies to control AdV infection 
The first AdV vaccination was developed and administered to military recruits in 
1971. It successfully reduced the AdV-associated respiratory diseases by 95% (15). 
However, the vaccine production was discontinued in 1996 which caused a re-emergence 
of AdV infections and associated symptoms among military population (15, 16). The 
same vaccine was reinstated in 2011 (17) and resulted in a steep decline in adenovirus 
cases from approximately 13,000 per year to a few hundred per year. Interestingly, only 
certain adenovirus types (4, 7, and 14) are problems in the military and are distinct from 
the types circulating in the civilian population (2, 5, 8, 11, and 21). Therefore, the current 
vaccines are relatively military specific. 
Over the decades since it was discovered, many attempts have been made to make 
additional therapeutics that inhibit AdV infection. Most of these trials have targeted the 
viral progeny which develop from the fully mature virus later during the replication stage 
of the AdV. One of the most commonly used strategies to block AdV infection is the 
inhibition of viral replication. More than 25 agents have been investigated to determine if 
they inhibit AdV viral replication. Notably, these agents were initially developed to treat 
DNA viruses in general, therefore they are non-specific for AdV infection. They prevent 
viral DNA replication by integration into the viral DNA and interfere with viral DNA 
elongation. An example (cidofovir) is commercially available anti-DNA viral agent, 
however, its selectivity against AdV infection is questionable due to the fact that it works 
in the late stage of viral entry and replication. In addition, the side effects developed from 
such agent limits its applicability specifically against AdV infection (18-20). Other 
antiviral agents that target the DNA replication include the cyclin-dependent kinase 
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(CDK) inhibitors which have been shown to inhibit the spread of AdV in vitro (21). A 
major consideration of this group is the wide range of off-target effects, due to the 
significant number of substrates available for CDK. Protease inhibitors are another group 
of antiviral agents that work by targeting proteases produced by the progeny virions in 
infected cells. Recently released simeprevir, the first FDA approved protease inhibitor 
against hepatitis C, could give hope for the potential development of anti-AdV protease 
inhibitors (22, 23). However, AdV produces many proteases and screening for potent and 
selective anti-AdV protease inhibitor may be time consuming process.   
As of today, there is no approved or effective treatment for AdV infection. Some 
antiviral drugs that non-selectively target DNA viruses are available and anecdotally used 
as a last resort against AdV infection due to limited efficacy and wide variety of side 
effects (24-26). Inhibition of AdV binding and entry is expected to be the most effective 
and prominent strategy to abolish AdV infection. The strategy for inhibition of AdV 
binding can be accomplished mainly by targeting the host cell receptor. AdV hijacks 
cellular proteins on the surface of host cells to bind and enter, hence, targeting one of the 
host cellular proteins may be an efficient way to prevent AdV entry or reduce spread in 
the body. There is an increased acceptance of targeting the host cells as an antiviral 
strategy. An example is the development of a sialic acid mimetic that would neutralize 
and inhibit AdV entry (27). The drug targets some of AdV species C, which use sialic 
acid as a co-receptor for binding and entry. The drug is now in phase II clinical trials in 
eye drop formulation under the name “APD-209” for prevention and treatment of 
conjunctivitis caused by AdV. 
Targeting the host cell as potential new anti-AdV or pro-gene therapy strategies 
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In contrast to anti-viral agents that target the specific viral pathogen, molecules 
that target the host may have promising outcomes for preventing AdV infection. A 
hallmark of such strategy is to target host proteins that are being hijacked by the AdV. 
This strategy would broaden the biological applications of the agent due to the fact that 
many AdVs use CAR as a receptor for binding and entry. Moreover, it can be used 
against other types of viruses that potentially use the similar cellular proteins. One 
advantage of targeting the host cell is the AdV life cycle depends on many cellular 
proteins within host cells. If these cellular proteins are targeted it will make it less likely 
for the virion to develop antiviral resistance, in comparison to the other antiviral agents 
that target the virions. For example, many microorganisms developed resistance against 
their antiviral agents either by releasing proteolytic enzymes to degrade the agent or by 
causing mutations in the drug active site. It would not be expected for the virions, 
however, to change its main cellular receptor, for example CAR, used for binding and 
entry. Therefore, agents that block AdV receptor would be more efficient against AdV 
infection with no resistance. Another advantage in targeting the host cell is to broaden the 
antiviral activity since many viruses share the same mode of infection toward their host 
cells. Finally, it is plausible that the effectiveness of traditional antiviral agents (i.e. 
acyclovir) would be enhanced if used in combination with an agent that targets one of the 
proteins necessary for viral cycle in the host cells. Such combination would also lower 
the required dose of the therapeutic agent which lowers the potential of developing side 
effects. 
Adenovirus as a vector for gene therapy 
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AdV is the most widely used vector for gene therapy (28, 29). It gives high 
expression of the gene it carries and it can infect both dividing and quiescent cells. 
Besides that, it has the capacity to deliver a large gene load efficiently and the dsDNA 
genome can be manipulated through standard molecular methods.   
               The most common AdV used as vector in gene therapy is AdV5 of which CAR 
is the primary receptor, and its transduction efficacy is dependent on CAR expression 
(30-32). Experimentally substituting the transmembrane and C-terminus of CAR with a 
glycophosphatidylinositol (GPI) tail (GPI-CAR) causes exclusive localization at the 
apical membrane of polarized epithelia and increases viral infection (33-35). Therefore, 
cells with high CAR expression at the apical membrane are transduced more efficiently 
than cells with low CAR levels and targeting the upregulation of apical CAR would be a 
good strategy for enhancing AdV mediated gene therapy.  
Upon intravenous administration in mice, AdV accumulates mainly in the liver, 
followed by spleen, heart, lung, kidney (36). Attempts have been made to change the 
distribution of AdV and tissue targeting of the AdV by targeting alternative surface 
receptors. One approach was the incorporation of an adaptor within the AdV fiber-knob 
structure that would recognize and target a ligand on the cell surface. In such way, the 
AdV will travel to the tissue were the receptor for the added ligand is expressed. An 
example of that is conjugation of Ad-FAB against a cellular receptor, such as fibroblast 
growth factor 2 (EGF2) (37, 38) to target cells with EGF2 receptor expression, or 
angiotensin converting enzyme (ACE) to target AdV to the pulmonary endothelium (39). 
Other adaptors used include an AdV that was fused with soluble CAR extracellular 
domain (sCAR ECD) along with EGF. This adaptation leads to increase AdV 
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transduction in EGF positive cells. The disadvantage of the adaptor-AdV fusion is that 
the two components were produced separately then fused together by chemical or 
physical ways. Such ways could affect the AdV structure or the genetic material that is 
being carried. Another disadvantage is that the progeny and nascent virions would lack 
these modifications, and therefore will bind to their original cellular receptor CAR, which 
may reduce viral transduction. 
Another strategy is genetic engineering of ligand within the AdV capsid structure 
so that it targets alternative cellular receptors. One of the most common engineered AdV 
was by incorporating the RGD motif within AdV structure (40-42). RGD are the 3 amino 
acid signals (Arginine, Glycine, Aspartic acid) that interact with surface integrins. AdV-
RGD, Ad5.SSTR/TK.RGD is the most promising example which has passed phase I 
clinical trials (43) and has proven to have high efficacy of gene transduction in vitro.   
In spite of the successful clinical trials using AdV as a vector, a major setback 
occurred in 1999 when 18-years old Jesse Gelsinger died after administration of a large 
inoculum (3.8 1013 particles) of AdV to restore ornithine transcarbamylase, an enzyme 
responsible for amino acid de-amination and ammonia metabolism in the body. Gelsinger 
died due to multi-organ failure and disseminated intravenous coagulation (44). 
Interestingly, a female patient who received a similar dose did not experience any such 
adverse effects (44). Although the administered AdV was replication deficient, high 
inoculums of AdV can still cause adverse effects. Therefore, molecules that increase the 
efficacy of AdV transduction would be able to overcome this drawback by allowing the 
administration of a low AdV inoculum.  
Coxsackie and Adenovirus Receptor (CAR) 
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               CXADR, the gene for CAR, was cloned and characterized in 1997 by three 
different groups (30-32). It is located on chromosome 21q11.1 and is composed of eight 
exons (45) spread over 54,000 nucleotides. The most abundant form of CAR protein is 
composed of one polypeptide chain (365 amino acids) which belongs to class I 
transmembrane protein (Figure 2). Its protein structure is composed of four domains, two 
of them form the extracellular D1 and D2 (214 aa), transmembrane domain (23 aa), and 
107 aa intracellular domains (30). The D1 extracellular domain forms homodimers and, 
thus, it is responsible for the cell adhesion function of CAR (46-49). The same aa within 
the D1 loop that mediate CAR-CAR adhesion also compose the binding site for AdV 
fiber knob. Neither the transmembrane domain nor the intracellular domain are important 
for viral binding and entry since replacement of these domains with a GPI-linked tail is 
sufficient to maintain equivalent infection (33). The cytoplasmic domain does play an 
important role in regulation and stability of the cellular levels of CAR. CAR is prone to 
many post translational modifications including, 1) phosphorylation at many tyrosine 
(Y269, Y294, Y313, and Y318), threonine (T29), or serine (S293, S323, and S332) 
residues (50) , 2) palmitoylation on cysteine C259, C260 (51), and 3) ubiquitination (52). 
Of particular importance, the extreme cytoplasmic domain of CAR encodes a PDZ 
binding domain motif -GSIV (or –ITTV in the 8 exon isoform of CAR), a motif that 
enables CAR to interact with PDZ domain containing proteins. The significance of CAR 
PDZ domain interactions is discussed in detail below (CAR interactions with PDZ 




CAR is expressed in most organs, but is predominantly expressed in the 
developing heart, airway epithelium, and brain (31, 53). In the heart, CAR levels change 
dramatically during embryonic development. During the early embryonic stage, CAR 
levels are high in the myocardium; this high concentration drops progressively as the 
heart matures (31, 54). Deletion of CAR leads to the formation of lesions and cardiac 
hemorrhaging (54, 55), ventricular hypertrophy, and defects in the sinoatrial valve (56). 
Asher et al. and others showed that in CAR KO mice, all embryos died 11-14.5 days post 
conception due to myocardial dysfunction (54-56). This indicates that CAR is essential 
for normal cardiac function during the early stages of embryonic development and 
suggests that CAR is a “pathfinder” receptor that mediates cardiomyocyte junction 
formation and integrity (57).  
CAR expression levels remain relatively high in the epithelial cells of several 
organs such as lung, liver, and intestine in adult organisms (58). It was predominantly 
expressed in cell layers lining body cavities including polarized epithelia (59). In well-
differentiated airway epithelia the eight exon isoform (CAREx8) is localized at the apical 
surface (45), where it can function as an anchor site for neutrophil binding on the 
epithelial apical surface (60). CAR was also found to localize at the apical membrane of 
retinal epithelial cells (61).  
Splicing of CAR 
Most adenoviruses and group B coxsackieviruses invade the human epithelium 
using CAR as a primary receptor (30, 31, 62). CXADR can express four isoforms of 
CAR, only two of them are transmembrane isoforms, namely CAR1 (CAREx7) and 
hCAR2 (CAREx8), which differ in their intracellular domain (ICD). The two isoforms are 
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structurally similar except for the cytoplasmic extreme C-terminal domain; 13 aa in 
CAREx7 and 26 aa in CAREx8 (Figure 2). Another crucial difference between the two 
isoforms is their localization in polarized cells. Whereas CAREx7 is buried within the 
basolateral junction adhesion complex of the human epithelium, and therefore, it is not 
directly accessible to the incoming airborne viruses, CAREx8 is localized at the apical and 
sub-apical air-exposed surface of human epithelial cells and provides a direct binding site 
for the incoming virus (45, 63, 64). Viral receptor isoform-specific localization and 
function has also been described for the poliovirus receptor. The poliovirus receptor 
(hPVR/CD155) has two transmembrane isoforms with differential localization in 
polarized epithelia (65). While hPVR resides on the basolateral surface, hPVR appears 
on the apical surface where it can mediate apical poliovirus entry. The regulation of 
apical versus basolateral localization for hPVR is also currently unknown but may rely on 






Figure 2. Alternative Coxsackievirus and adenovirus receptor (CAR) spliceforms.  
The two isoforms are only different in the extreme C-terminal domain with 26 aa in 
CAREx7 replaced with 13 aa in CAREx8. Adapted from (45). 
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CAREx8 mediates adenovirus infection of primary airway epithelia 
The first step for initiation of AdV infection is binding to a cell surface receptor. 
Except for group B AdV which use CD46 for binding and entry (66-69), most AdV 
serotypes use CAR as a common receptor for binding and entry into cells (70, 71).  
Following binding, AdV requires a secondary interaction with integrins (72).  Integrins 
are heterodimeric cell surface transmembrane proteins known to be involved in cell 
adhesion, migration, growth, and differentiation. Integrins ανβ1, ανβ3, and ανβ5 are the best 
described AdV co-receptors and are known to enhance the AdV entry step into host cells 
(72, 73). They promote AdV entry by binding to the RGD motif found within the AdV 
penton base which facilitate virus entry. AdV then internalized via clathrin-mediated 
endocytosis (74). The signaling pathway that causes dynamin and clathrin triskelions to 
be recruited to the AdV binding site and the surrounding milieu is currently unknown. 
However, endocytosis of the clathrin-coated vesicle is followed by stepwise dismantling 
of the virion fiber knobs and endosomal escape of virion to the cytoplasm by pH 
dependent process (75, 76). Adenovirus has also been shown to enter by non-clathrin 
mediated endocytosis pathways including macro- and micropinocytosis (77, 78). Once in 
the cytoplasm, the virion capsid interacts with microtubule motor proteins that lead to the 
nucleus. Additional uncoating of the capsid occurs at the nuclear pore which then allows 




Figure 3. The process of AdV entry and infection. 
AdV binds the cell surface receptor CAR. Integrins function as co-receptor for AdV to 
facilitate its entry. AdV is endocytosed by clathrin-mediated endocytosis followed by 
viral escape by endosomal acidification which causes stepwise dismantling of the 
virion structure. The virion travels along microtubules and binds to nuclear pore 
complex. The virion then ejects its DNA into the nucleus which triggers viral 
replication. Adapted from Coughlan et al., 2010 (81). 
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The pulmonary epithelium is a highly characterized system lining the respiratory 
tract. It exposes a vast surface area to the ambient air, thereby allowing efficient gas 
exchange of oxygen and the metabolic waste product carbon dioxide. It is also the first 
line of defense for an airborne microorganism to infect the respiratory system. The 
pulmonary epithelium is characterized by its ability to polarize and form tight junctions 
that seal the basolateral surface of the respiratory tract from pathogenic microorganisms 
on the apical surface. For a long time, the dominant isoform, CAREx7, was believed to be 
the only primary epithelial AdV receptor and viral access to basolateral CAREx7 required 
a transient or sustained break in the tight junction (77). The discovery of CAREx8 causes 
paradigm shift from the traditional knowledge about AdV infection and gives incentives 
to researchers to look for a strategy to target the apically localized CAREx8 isoform. 
We have discovered that the eight-exon CAR isoform (CAREx8) localizes to the 
apical membrane of polarized primary human airway epithelia and mediates apical AdV 
entry (Figure 4) (45, 63, 64). CAREx8 is the AdV receptor at the apical surface of 
polarized epithelia and the susceptibility of an epithelium to adenoviral infection can be 
directly impacted by either increasing or decreasing CAREx8 expression (Figure 5). This 
discovery has opened the doors toward investigations and discovery of new therapeutic 
strategies aimed to downregulate CAREx8 for the purpose of inhibition of AdV infection, 







Figure 4. CAREx7 and CAREx8 localize and behave distinctly in well-differentiated 
primary human airway epithelia (HAE).  
(A) CAREx7 (green) overlaps (yellow) and is basolateral to the tight junction protein 
ZO-1 (red). (B) CAREx8 (green) localizes to an apical compartment and is distinct from 
ZO-1 (red). The arrow indicates CAREx8-specific staining above the ZO-1 delineated 
tight junction. (C) Background staining with pre-immune rabbit serum (green) and ZO-
1 (red). Over-expression results in (D) CAREx7 localization primarily at the basolateral 
junctions and E) CAREx8 localization diffusely and at the apical surface of HAE.  (F) 
Augmenting CAREx8 expression significantly increases apical adenovirus, encoding the 
gene for β-Galactosidase (Adβ-Gal), transduction over GFP or CAREx7 expressing 
epithelia *p<0.01. Dotted line represents support membrane; AP, Apical surface; BL, 






Figure 5. Accessibility of CAR to adenovirus entering from the lumen of the 
airway. 
(A) CAREx7 localizes beneath the tight junctions at the basolateral surface of polarized 
epithelia and is not accessible to incoming AdV. (B) CAREx8 localizes at the apical 
surface and in a recycling endosome. Apical CAREx8 allows AdV to bind, internalize, 




PDZ domains were first identified in three proteins: postsynaptic density protein 
(PSD95) (82), its Drosophila homologue discs large tumor suppressor (DlgA) gene 
product (83)  and zonula occludens-1 (ZO-1) (84), a tight-junction protein. PDZ domain 
containing proteins are a huge class of “scaffolding proteins” that can simultaneously 
interact with several proteins and are involved in screening and sorting of many 
intracellular and transmembrane proteins. They play an important role in the trafficking 
and stability of many proteins, including apically localized proteins such as CFTR (85). 
The membrane-associated guanylate kinases (MAGUKs) are a family of scaffolding 
proteins responsible for organizing many groups of proteins at the cell-cell junctions (86, 
87). MAGUKs are characterized by having a SH3 domain, a guanylate kinase domain 
(GK), WW domains, and multiple PDZ domains (Figure 6). Most MAGUKs family 
members localize at the cell junction and this localization occurs in the absence of the 







Figure 6. Examples of members of the membrane associated guanylyl kinases 
(MAGUK) family. 
Most MAGUKs share a SH3 domain (yellow), a guanylate kinase domain (red) and 
PDZ domains (blue). Modified from (89) 
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Individual PDZ domains are composed of 80-100 amino acids that have a 
structurally well-defined interaction ‘pocket’ that interacts with PDZ binding domains 
(90). The domains can recognize short C-terminal sequences in target proteins, called 
PDZ binding domains that contain one of four classes of consensus sequences, type I 
(S/T-x-Ф–COOH), type II (Ф-x-Ф–COOH), type III (-x-Ф–COOH) and type IV (D-x-
V–COOH) where (X) is any amino acid, (Φ) is hydrophobic aa (V, I, L, A, G, W, C, M, 
F), and (Ψ) is basic aa (H, R, K)  (90-93).  We have shown that the PDZ domain 
containing cellular protein, MAGI-1 (member of MAGUKs family), is a master switch 
for CAREx8 protein levels and apical AdV infection of polarized cells (63).  
The function of each PDZ domain containing protein is diverse. Many of them 
such as LNX1 (94), MARCH2 (95), and PDLIM2 (96) were shown to contain a ubiquitin 
ligase in their structure. Others, such as Crumbs, Scribble, and Par are suggested to be 
responsible for establishing apical and basolateral polarity in epithelia cells (97). The 
majority of them, MUPP1, PATJ, MAGI-1, and ZO-2, lack a catalytic domain and 
instead form a multiple protein-protein interaction module with tight junction molecules. 
Alternatively, they may be responsible for proper trafficking and subcellular localization 
of many receptors and ion channels such as such as the β-adrenergic receptor (98), 
potassium  channels (99), sodium channels (100), and NMDA receptors (101). 
CAR interactions with PDZ domains containing protein 
The cellular stability of CAREx8 protein level is regulated by a PDZ domain 
containing protein called MAGI-1 (Membrane Associated Guanylate Kinase, WW and 
PDZ Domain Containing 1). MAGI-1, is a master switch for CAREx8 protein levels and 
apical AdV infection of polarized cells (Figure 7) (63). We found that the effect of 
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MAGI-1 on CAREx8 is mediated by the PDZ binding domain of CAREx8 located at its 
extreme C-terminus domain. Interestingly, two PDZ domains within MAGI-1 recognizes 
the C-terminal domain of CAREx8, namely PDZ1 and PDZ3. It is speculated that the 
concentration of CAR at the membrane is regulated mainly by PDZ domain containing 
proteins. Indeed, CAR has been shown to interact with many PDZ domain containing 
proteins located at the interior side of the membrane including MUPP-1 (102), MAGI-1b, 
PICK1 and PSD-95 (103), LNX and LNX-2 (104, 105), and ZO-1 (47). These 
interactions are not only relevant for regulating the concentration of CAR via interactions 
with scaffolding proteins such as MAGI-1b (63), but also for the proper trafficking of ion 






Figure 7. MAGI-1 PDZ3 decreases viral infection, while PDZ1 inhibits MAGI-1-
mediated CAREx8 suppression to allow adenovirus infection. 
CAR-deficient CHO-K1 cells were (A) single, or (B) double transfected with CAREx8, 
full length MAGI-1 (black bars), PDZ1 domain (dotted bars), or PDZ3 domain (white 
bars), and balanced with empty pcDNA3.1 plasmid (gray bars), followed by AdV-β-
Gal (MOI 100) transduction. Adapted from (63). 
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MAGI-1, an easy viral target 
Many viral proteins contain PDZ binding domains and subvert the activity of 
cellular PDZ domain containing proteins to enhance the viral lifecycle and/or increase the 
virulence of the virus (107-109). Of particular importance here, MAGI-1 interacts with 
over 40 cellular and viral proteins (110). One of these proteins is the human papilloma 
virus (HPV) E6 protein which binds to and stimulates MAGI-1 degradation to disrupt 
tight junctions and promote oncogenesis (108). MAGI family proteins exhibit the 
strongest binding to and most efficient degradation by E6 via proteasome-mediated 
degradation (108, 111-113). Recent findings suggest that HPV E6-mediated degradation 
of MAGI-1 promotes tight junction disruption in epithelial cells (114). Therefore, many 
viral proteins may have been developed to hijack the host cell function in order to 
promote their virulence and enhance their replication.  
Targeting protein interactions by cell permeable peptides  
 Rapid transduction of proteins into cells can be facilitated by cell permeable peptides 
(CPP; also called cell penetrating peptides) (115-117). The 11-amino acid minimal 
transduction domain of HIV-1 TAT (residues 47-57) can facilitate protein entry into a wide 
variety of cells both in vitro and in vivo (118, 119). Many other CPPs have been described 
from octa-arginine to AdV dodecahedrons (115, 120, 121). TAT-CPPs are in clinical trials 
and clinically approved protein-based therapies are available (e.g. surfactant proteins, 
DNase) (122-124). Interactions with the fifth MAGI-1 PDZ domain (PDZ5) has been 
targeted in MDCK cells using CPP and caused the disruption of the MAGI-1 interaction 
with β-catenin, an important cellular cell junction and signaling protein (125). Moreover, 
CPP that target PDZ domain interactions with the neuronal scaffolding protein PSD-95 
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protect against neuropathic pain and ischemic brain damage in murine models (126, 127). 
Interestingly, the PDZ binding domain motif of CFTR is required for its degradation (95) 
and  modified cell permeable peptide has been used recently to rescue CFTR activity from 
its PDZ domain containing protein that mediates CFTR degradation (128). Moreover, 
disturbing the PDZ interactions has been used to protect against long term potentiation and 
depression (129), Huntington’s disease (130, 131), cystic fibrosis (132), and cancer (133). 
Therefore, targeting PDZ dependent interactions are potential future therapeutics for many 
diseases and disorders (90). 
Model for altering CAR trafficking and degradation in polarized cells 
CAREx8 can interact with two MAGI-1 PDZ domains, PDZ1 and PDZ3, which 
regulate CAREx8 levels in opposing ways. Results showed that the MAGI-1 PDZ3 
domain is responsible for CAREx8 degradation. However, when CAREx8 interacts with the 
MAGI-1 PDZ1 domain, CAREx8 was rescued from MAGI-1 induced CAREx8 degradation 
(Figure 8). The mechanisms behind how these domains have opposing activities are 
currently unknown. Understanding these mechanisms will have significant clinical 
implications for prevention of wild-type viral infection or improving AdV-mediated gene 






Figure 8. Model of MAGI-1 mediated CAREx8 regulation. 
(A) MAGI-1 PDZ3 domain mediates CAREx8 degradation which suppresses AdV 





The interaction of CAREx8 with MAGI-1 requires the CAREx8 PDZ binding 
domain (45). Previous data showed that deletion of the CAREx8 C-terminal ITVV PDZ 
binding domain sequence allows CAREx8 protein expression at cell junctions, where no 
co-localization with MAGI-1 is observed (45). However, the PDZ binding domain is not 
sufficient and the degradation phenotype requires the upstream CAREx8-specific 
sequence. Interestingly, switching the CAREx7 GSIV sequence with the CAREx8 ITVV 
sequence does not switch the degradation phenotype between the two isoforms (45). 
These data show that the ITVV sequence interacts with MAGI-1 but that the last 9 amino 
acids of the CAREx8 C-terminal domain sequence play an important role in degradation. 
We hypothesize that this reflects a CAREx8 specific interaction with MAGI-1 directly and 
that such interactions can be controlled by using specific cell permeable peptides to 
interrupt the MAGI-1 PDZ domain interactions with CAREx8 (Figure 9). Notably, other 





Figure 9. Model of TAT-peptide-mediated MAGI-1 PDZ domain blockers. 
(A) It is hypothesized that TAT-PDZ1 binding peptides (TAT-E6 and TAT-NET1) 
bind to and block the PDZ1 domain increasing CAREx8 - PDZ3 domain interactions 
that promote CAREx8 degradation and suppress AdV entry. (B) It is hypothesized that 
TAT-PDZ3 binding peptides (TAT-ESAM and TAT-CAREx8-9C) bind to and block the 
PDZ3 domain increasing CAREx8 – PDZ1 domain interactions that rescue CAREx8 from 
degradation and increase AdV entry into the epithelial cells. Note that it is expected 
that TAT-CAREx8-9C will bind to both PDZ1 and PDZ3 but will function like a PDZ3 






My central hypothesis is that decoy peptides that interrupt one or both of the 
interactions between MAGI-1 and CAREx8 can destabilize apical CAREx8 protein to 
abrogate adenoviral entry or upregulate apical CAREx8 protein to enhance AdV gene 
therapy.  
Specific aims 
Specific aim 1: To determine the cellular mechanism of “attenuator” cell permeable 
peptides that bind to the endogenous MAGI-1-PDZ1 domain and their effect on AdV 
infection.   
Specific aim 2: To determine the cellular mechanism of “potentiator” cell permeable 
peptides that bind to the endogenous MAGI-1-PDZ3 domain and their effect on AdV 
infection. 
Specific aim 3: To determine whether cell permeable peptides that bind to the 
endogenous MAGI-1-PDZ1 or MAGI-1-PDZ3 domain would change AdV infection in 
vivo. 




Figure 10. Model illustration of the hypotheses and specific aims. 
(A) MAGI-1 regulates the protein level of CAREx8 by two of its PDZ domains. (B) 
TAT-PDZ1 peptides bind to and block the PDZ1 domain forcing CAREx8 - PDZ3 
domain interactions that promote CAREx8 degradation and suppress AdV entry (Aim 1). 
(C) TAT-PDZ3 peptides bind to and block the PDZ3 domain forcing CAREx8 – PDZ1 
domain interactions that rescue CAREx8 from degradation and increase AdV entry into 




Table 2. MAGI-1 PDZ domain interacting partners 
Protein 
(Gene) 




α-actinin 4 (ACTN4) STALYGESDL 5 (134) 
BAI-1 QDIIDLQTEV 3, 4 (135) 
β-Catenin (CTNNB1) NQLAWFDTDL 5 (136) 
Cadherin 23 (Cdh23) METPLEITEL 4 (137) 
CAREx8 PYKTDGITVV 1, 3 (63) 
Carom (FCHSD2) KIEDVEITLV 4, 5 (138) 
ESAM PAQSQAGSLV 3 (139) 
JAM4 PQKVRNVTLV 1, 4 (140) 
Kir4.1 SALSVRISNV 5 (141) 
Megalin (LRP2) ANLVKEDSDV 5 (142) 
Nephrin LPFELRGHLV 2, 3 (143) 
NET1 QSGGKKKETLV 1 (144) 
PTEN DQHTQITKV 2 (125) 
TRIP6 ELSATVTTDC 5 (145) 
Beta1AR (ADRB1) PGFASESKV 1 (146) 





HPV E6 SRTRRETQL 1 (112) 
Ad9 E4Orf1 FPSVKIATLV 1, 3 (108) 
Influenza A virus NS1 KMARTARSKV 1, 5 (149) 








CHAPTER 2: Materials and Methods 
Materials 
Cell Lines 
Epithelial and non-epithelial cell lines were used for various experiments (Table 
3). 3T3 J2 cell line was obtained from Howard Green, MD (Harvard University). Primary 
HAE (Donor 2) and the HEK 293 cell line were obtained from the University of Iowa 
Cell Culture 
Core. The remaining cell lines were purchased from ATCC, Virginia. All cell lines were 
stored in liquid nitrogen in the Department of Biological Sciences at Wright State 
University, Dayton OH. 
Culture Media 
Cells were cultured in appropriate sterile culture medium (GibcoTM Invitrogen 
Corporation, Grand Island, NY) supplemented with 10% fetal bovine serum (except 
MDCK, supplemented with 5% FBS) immediately after removing the cells from liquid 
nitrogen. After stimulation of growth, the culture medium was further substituted with a 
final medium-serum mix containing penicillin and streptomycin antibiotics. The 
powdered culture medium, containing L-glutamine and 25 mM HEPES buffer, was 
dissolved in distilled deionized water (ddH2O) from a Nanopure Millipore Water System. 
All culture media were supplemented with 2.024 g/L sodium bicarbonate. The 
solution was adjusted to pH 7.0 to 7.1 with 1 N HCl dropwise. The culture media 
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solutions were sterilized through a 0.2 μm-pore cellulose nitrate Nalgene vacuum 
filtration apparatus. 
Sterile media were supplemented with 0.5% penicillin/streptomycin and the appropriate 
heat inactivated fetal bovine serum by appropriate volume percentage. The final culture 
media was stored in 500 ml Pyrex bottles and kept at 4ºC. 
Competent Cells 
BL21 derivative competent cells (Rosetta) were used for transformation and 
protein purification experiments according to their unique properties (see protein 
purification section). Competent E. coli DH5 alpha were used to store the transformed 
plasmid expression protein in glycerol stock (-80ºC).  
TAT-PDZ Peptides 
TAT-PDZ peptides used in this study and their binding affinities are listed in Table 4. 
Antibodies 
The antibodies used in this study are listed in Table 5. 
Primers 
The list of primers used in this study is shown in Table 6. 
SiRNA 
The list of siRNA used in this study and their target sequences is shown in Table 7. 
Inhibitors 




Table 3. List of cell lines used in the study 
Cell Name Cell Type ATCC No Media 
Seeding 
(0.5 ml) 


























CCL-34 EMEM 4 x 105 
HeLa Cervix Epithelia 30-2003 EMEM 2 x 105 








Table 4. TAT-PDZ peptides used in this study and their binding affinities 







TAT-CAREx8-9c YKTDGITVV 23± 10 N.I 4 ± 2 
TAT- CAREx8- AA-
9c 
YKTDGIAVA 113± 28 N.I 71± 19 
TAT-NET1 SRTRRETQL 28 ± 11 N.I N.I 
TAT-E6 GGKKKETLV 15 ± 4 N.I N.I 
TAT-Scramble QGDITVKVT N.I N.I N.I 
TAT-ESAM AQSQAGSLV N.I N.I 17 ± 5 
TAT-ADAM17-9c RVDSKETEC N.I 35 ± 8 N.I 
N.I, No detectable interactions
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Table 5. Antibodies used in the study 
Table 2. Antibodies used in the study 
Antibody Vendor Cat # Dilution for WB/IF 
Mouse primary antibody 
Actin Ambion AM4302 1:2000-1:3000 












Myc Cell Signaling 2276S 1:1000 
ZO-1 (dog) Invitrogen 33-9100 1:200 
ZO-1 (human) BD Bioscience 610967 1:200 
Rat Primary Antibody 
Rab 4,5,7,9,11 Cell Signaling 9385S 1:500-1:1000 









GFP Invitrogen A11122 1:1000-1:2000 
MAGI-1 Novus  1:200 













RB1660P0   5µg/ml 











Goat IgG Alexa Fluor Labeled Secondary Antibody  
Mouse A488 Invitrogen a10667 1:1000 
Mouse A568 Invitrogen a11004 1:1000 
Rabbit A488 Invitrogen a11008 1:1000 
Rabbit A568 Invitrogen a11036 1:1000 
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Table 6. List of primers and their sequence 
Primer Set Forward Primer 5' → 3' Reverse Primer 3' → 5' 



































Table 7. List of siRNA used in the study 
siRNA Vendor Cat # Target Sequence 
ADAM17 Dharmacon A-003453-13 
GGAUGUAAUUGAACGAU
UU 
ADAM17 Dharmacon A-003453-14 
CCAAGAUUUUGAUAUGG
GA 
ADAM17 Dharmacon A-003453-15 
GCAUCAAUACUUUUGGA
AA 
ADAM17 Dharmacon A-003453-16 
GGUCUAUUUCUAGUUAU
UA 
ON-TARGET plus Dharmacon D-001810-01-05 
UGGUUUACAUGUCGACU
AA 




Table 8. Inhibitors used in this study 
Inhibitor  Vendor Cat # 
MG-132 Fisher Scientific AP81-5-15A 
TAPI-1 Calbiochem 579051 
TIMP3 R & D systems 973-TM 
Compound E Calbiochem 565790 





Cell culture maintenance 
Cell culture techniques were performed under a laminar flow hood using aseptic 
techniques. Cell cultures were stored and grown in 25 or 75 cm2 tissue culture flasks 
within a humidified incubator at 37ºC and 5% CO2 concentration. The media-serum mix 
was changed in the flasks based upon a pH change from 7.1 to about 6.0, as indicated by 
a color change of the media from pink to yellow. As cells began to divide and reach 
approximately 80% confluency, the cell cultures were divided into new flasks using a 
cells to media ratio of between 1:5 and 1:20 after removing attached cells with 0.25% 
Trypsin-EDTA (Mediatech, Inc., Manassas, VA). All flasks were supplied with new 
media-serum mix to a final volume of 5 ml in a 25 cm2 tissue culture flask and 10 ml in a 
75 cm2 tissue culture flask. Cell viability was verified before each experimental set using 
the trypan blue exclusion test (151). Dead cells appeared blue, as their cell membranes 
are permeable to the dye upon death. Cell viability above 80% was considered suitable 
for experiments. 
Determination of cell concentration (hemocytometer) 
The technique reported was used during cell seeding before transfection and 
adenovirus infection. Adherent monolayers of cells were trypsinized from 1-2 flasks and 
combined in a 50 ml centrifuge tube. The tube was centrifuged at 150 rcf for 5 min at 
4ºC. The supernatant was aspirated and the cells resuspended in 1 ml culture medium and 
mixed gently by pipetting up and down. A clean coverslip was centered on a 
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hemocytometer between the outside railings over the two counting grids. A drop (10 µl) 
of well-mixed cell suspension was placed at each notch. The drop was added once to 
ensure even distribution of cells. Cells were counted with a push button counter using 
400 X total magnification. Cells were counted in the four corner squares (1 mm X 1 mm) 
of the cytometer. These squares were 1/400 mm2. The average value of the total cells 
counted in the 4 squares was multiplied by 104 to determine the number of cells per 
milliliter. The volume of the mixture was adjusted by dilution with culture media to an 
appropriate concentration, depending on the particular assay. 
Peptide preparation and treatment 
TAT-Peptides were synthesized by the Genescript peptide synthesis core 
(Genescript, MO) as a white powder. A list of all synthesized peptides and their binding 
affinities is shown in Table 4. A stock solution of approximately 1 mM of each peptide 
was prepared and dissolved in PBS. For peptide treatment, cells were washed with PBS 3 
times and treated with small volume (50µl of 1 - 100 µM dose) of peptide directly into 
cells. Serum free Opti-MEM was added and incubated for 1 hr or as described in the text. 
Media was changed to Opti-MEM containing fetal bovine serum for 4-5 hrs. After that 
cells were washed again and either fresh media added or lysed with lysis buffer 
containing protease inhibitor depending on the experiment. Unless otherwise indicated, in 
conditions where CAREx8 was induced using inducible MDCK epithelial cells, 100 µM of 
TAT-peptides were used in treatment for a period of 4-5 hrs.    
Matrix Assisted Laser Desorption Ionization-Mass Spectrometry (MALDI-MS) 
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Polarized MDCK cells (≈ 1*106) were incubated for 60 min at 37°C with 1 or 50 
µmol/l TAT-CAREx8-9c peptide in starvation media containing (Opti-MEM with earle’s 
salt).  After 1hr incubation, cells were washed with PBS, and lysed with lysis buffer 
containing 2 mmol/l PMSF and 0.1% Trifluoroacetic acid (TFA). Lysate was washed 
with 50 mM sodium acetate buffer containing 150 mM Nacl. Cells were centrifuged at 
135,000 rpm. Equal amounts of protein lysate were transferred into new tubes. Peptides 
were purified using C18 Ziptips (Millipore, Billerica, MA) according to a previously 
published procedure (152). Briefly, the Ziptip was activated with 100% acetonitrile, 
followed by washing 3x with 0.1% TFA. After that, the sample was loaded into column 
by repeated pipetting 20-30 times. Column was washed again 3 times with 0.1% TFA. 
Finally, peptide was eluted with 95% acetonitrile containing 0.3% TFA. Elution was 
spotted on a Brucker protein plate chip containing (alpha cyano-4- hydroxycinnamic acid 
in 70% acetonitrile, 10% acetone, 0.3% TFA). 
Mass spectra were obtained using a Bruker Autoflex III smart beam MALDI 
TOF/TOF instrument. A total of 7,000 laser shots were acquired randomly for each spot 
at a laser frequency of 100 Hz. The mass spectrum was accumulated and normalized to 
the peak m/z in each spectrum.  
Fluorescently-labelled peptide internalization 
TAT-CAREx8-9c peptide was synthesized (genescript, NJ) and tagged with 
TAMRA (red fluorescence). Cells were treated with the fluorescent peptide at different 
time points after which they were washed with PBS, fixed with 1% PFA in methanol and 
cover slipped with DAPI solution. Images were taken by confocal microscope at 60X oil 
immersion magnification.  
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Testing for expression of proteins in E. coli 
Confirmed clones of MAGI-1 PDZ domains (pHH2 plasmids) were transformed 
into E.coli using the Rosetta strain of competent cells (EMD chemicals, Gibbstown, NJ). 
Rosetta competent cells are BL21 derivatives that supply tRNAs for AGG, AGA, AUA, 
CUA, CCC, GGA codons on a chloramphenicol-resistant plasmid and are therefore 
capable of expressing eukaryotic proteins that contain codons rarely used by E. coli. 
Transformation was done by adding 100 ng pHH2 plasmids into 10 µL competent cells in 
a 2.0 ml centrifuge tube and kept on ice for 30 min. The tube was heat shocked for 45 sec 
at 42°C and kept back on ice for 2 min. 250 µL SOC medium was added to the cells and 
the tube incubated for 1 hr at 37°C with shaking at 200 rpm. Each vial of transformed 
cells was then spread on ampicillin (100 μg/ml) and chloramphenicol (10 μg/ml) 
containing LB agar plates (20% and 80%) and incubated overnight at 37°C. The next 
day, 3 - 9 colonies of each plasmid were grown overnight as 1 colony per 5 ml of LB 
broth containing ampicillin (100 μg/ml) and chloramphenicol (10 μg/ml). Next day, 500 
µL of each overnight culture was subcultured into three 5 ml of LB (Amp+, Chl+) broth 
(a total of 15 ml culture/colony) and grown until an OD600 od 0.6-0.8 was contained, after 
which 1 ml of culture was transferred from each sample into another tube and stored at -
20°C as the zero hour non-induced sample. 10 µL of 100 mM IPTG was added to each 
remaining 2 ml culture to induce protein expression and continued incubation at 37°C. 1 
ml samples were taken at 1, 2, 4, 6, 8, 12, 24 hrs. All samples were centrifuged at 9,500 
rpm, 4°C for 10 min. Each pellet was resuspended in 100 µL PBS and sonicated with 
pulses to completely lyse the cells. The lysate was again centrifuged after which the 
supernatant was transferred into fresh tubes on ice. Protein samples were mixed with 2X 
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SDS denaturing buffer and incubated at 75°C for 5-10 min with shaking at 300 rpm. 
Then, 35 μl of protein from each sample was subjected to SDS-PAGE and the gels were 
stained with Coomassie blue to look for a protein band of appropriate size. The sample 
with the highest amount of protein after induction was chosen and this clone was used to 
make and purify the protein of interest. Desired clones were grown in LB broth and 
stored at -80°C in cryogenic tubes containing 50% glycerol (1:1 50% glycerol: cell 
culture ratio) to make the glycerol stock. 
Coomassie blue staining 
Gel containing 10% acrylamide was fixed with solution contain 50% ethanol and 
7% acetic acid. Then, the gel was immersed in 0.075% stain solution in 10% acetic acid 
and 50% ethanol for 10 min and then washed 3X with ddH2O. To destain, the gel was 
placed in 100 ml of 5% ethanol and 7.5% acetic acid with gentle agitation and changed to 
fresh destain solution every half hour until the gel was clean enough to see protein bands 
clearly. The gel was transferred into 0.5% acetic acid and subsequently soaked in 4% 
glycerol for 2 hr. The gel was dried at 70°C for 50 min in a gel dryer vacuum system 
(BioRad, model 583) and scanned for image. 
Purification of proteins from Rosetta bacteria 
On the evening of the first day of purification, Rosetta E. coli containing the 
appropriate pHH2 plasmid were taken from a glycerol stock and streaked on a LB 
(amp+/chlo+) agar plate and grown at 37°C overnight. The plate was removed the next 
morning and kept at room temperature until evening. A 40 ml LB (amp+/chlo+) broth 
was inoculated with a single colony from the plate and incubated at 37°C and 200 rpm 
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overnight in a shaker. The overnight culture was subcultured into 1 L of pre-warmed LB 
broth and incubated at 37°C for about 4 hours (until OD600 1.5-1.9). 1 ml of uninduced 
sample was taken for gel analysis before adding 1 ml of 100 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and continued shaking for about 4 hours. 1 ml of induced 
sample was also taken for gel analysis. The 1 L culture was then centrifuged in 500 ml 
bottles at 8,500 rpm, 4°C for 10 min in a Sorvall centrifuge. The pellet was stored at -
80°C with 400 µL of 100 mM PMSF. 
Pellets from the 1 L culture were resuspended in 10 ml 2X L&C buffer (Tris-
based elution buffer; 400 µL 1 M Tris, pH 8.0, 0.35 g NaCl, 2 ml glycerol in 10 ml 
solution), 10 ml 2X protease inhibitors cocktail (Sigma-Aldrich, St Louis, MO Cat # 
S8830), 40 µL 0.5 M EDTA and 20 µL 1 M DTT. The resuspended cells were sonicated 
on ice for 6 min with 30 sec pulses and centrifuged at 9,500 rpm at 4°C for 20 min. The 
supernatant was filtered through 1.2 micron filters then through 0.2 micron (Whatman, 
GE Healthcare REF 10 462 261) to remove any debris. The clarified lysate was pumped 
through a Fractogel GST-bind cartridge (EMD) using a BioRad pump at 4°C according to 
the manufacturer’s instructions. The Fractogel cartridge bound the GST-tagged proteins 
while other synthesized proteins pass through the column. Briefly, after pumping the 
lysate through the cartridge, the column was washed with 2 ml 1X L&C buffer, followed 
by 5 ml ATP wash buffer (2X L&C buffer, 10 mM ATP, 50 mM MgCl2, 1.3 ml ddH2O) 
and finally, 12 ml 1X L&C buffer containing 1 mM DTT and 1 mM EDTA. To excise 
protein without any tag, a GST-tagged PreScission protease mix (1 ml L&C buffer 
containing DTT and EDTA and 50-100 µL of protease) was pumped in the column and 
allowed to circulate through the system for 4-6 hours. Typically, the protease was 
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originally at 1.5-6 mg/ml and desalted. The material in the recirculated tube was collected 
as elution 1 (E1). L&C buffer containing DTT and EDTA was pumped through the 
column to collect at least 3 more fractions of about 1 ml each and labeled E2, E3 and E4 
respectively. The fractions contained tag-free proteins which were quantified and the 
quality verified using SDS-PAGE. 4 ml of reduced glutathione buffer (0.01 g/ml of 1X 
L&C buffer) without DTT or EDTA was pumped into the column to remove the GST 
tags and protease and the column was subsequently washed with 10 ml L&C buffer 
without DTT or EDTA to regenerate the column for future use. The column was stored at 
4°C for other purifications while the purified protein was stored at -80°C. In any situation 
where GST-tagged protein was purified, the bound protein was eluted directly with 
reduced glutathione after washing thereby skipping the use of protease. In other 
situations, where a GST tagged protein band is noticed with the pure protein, the GST 
protein was removed by incubating with GST slurry beads (Goldbio, MO) for 4 hrs at 
4°C. The protein-slurry mixture was separated by centrifugation at 4°C, then the pure 
protein is taken to be dialyzed. Results showed a high yield of pure protein of both PDZ1 
and PDZ3 domain (Figure 11). ADAM17 cytoplasmic domain was cloned and purified 
using the same approach. First, ADAM17 coding sequence was confirmed by double 
digestion and sequencing (Figure 12). Then, ADAM17 cytoplasmic domain was cloned 
in pHH2 plasmid, transfected into Rosetta cells, and the protein was purified as explained 
above. A high concentrated purified ADAM17 cytoplasmic domain (MW = 17 KD) was 
eluted (Figure 13). Note that the protein band intensity decreases as more protein was 




Proteins were purified with a Tris-based buffer that did not allow proper labeling 
of the proteins with fluorophores for subsequent experiments. Tris-based buffer was 
replaced by dialysis against 3 changes of 2 L dialysis buffer (PBS) at 4°C for minimum 
of 16 hours (2 hrs; 2 hrs; overnight) using a Slide-a-lyzer dialysis cassette (Thermo 
scientific). Each cassette was removed aseptically from its pouch and immersed in 
dialysis buffer for 2 min to hydrate the membrane. 2 ml protein sample was added and 
the cassette was floated vertically in the dialysis buffer and stirred gently. A syringe was 
used to transfer protein samples into and to remove samples from the cassette after 
dialysis as directed by the manufacturer. 
Protein labeling 
Purified MAGI-1 PDZ domain proteins without GST tag were labeled with 
FluoroLinkTM Ab Cy3 labeling kit (GE Healthcare Cat # PA33000) according to the 
manufacturer’s recommendations. Protein solution (1 mg/ml) was added to the vial of 
coupling buffer, mixed gently, then transferred to the vial of reactive dye and incubated at 
room temperature with mixing every 10 minutes. While the labeling reaction was 
incubating, 13 ml of fresh elution buffer was added to the column for priming. The 
antibody-labeling mixture was carefully added to the top of the column and allowed to 
enter the resin. 2 ml of elution buffer was added to the column to separate the mixture 
into a faster moving pink (Cy3) band of labeled protein from the unconjugated dye. An 
additional 2.5 ml of elution buffer was then added to the column that will help to elute the 
pink band. The labeled protein was collected in a clean tube. 
Quantification and calculation of D/P ratio 
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Cy3 bisfunctional dye characteristics Cy3  
Formula Weight 949.11  
Absorbance max 550nm  
Extinction max 150000M-1cm-1  
Emission max 570nm  
Quantum Yield >0.15*  
* = for labeled proteins, D/P = 2 
An aliquot of the labeled protein was diluted such that the maximum absorbance 
was 0.5 to 1.5 AU. The absorbance of each labeled protein was measured at 280 nm, 552 
nm (Cy3) after which protein concentration was determined with Bio-Rad reagent. 
Estimation of Cy3 final Dye/Protein (D/P) Ratios 
[Cy3 dye] = (A @ 552nm) / 150000 ( [ ] )= concentration) 
[Protein] = [A @ 280nm – (0.08 * A @ 552nm)]/ molecular weight of protein 
             D/P final = [dye]/[protein] 
Graphing and data analysis 
All graphs and data analysis were made using Prism software version 6 
(GraphPad, CA). Each experiment was done in triplicate and data were plotted as Mean± 
SEM. The binding affinity (Kd) was determined using the function of non-linear 





Figure 11. MAGI-1 PDZ domains protein purification. 
PDZ1 and PDZ3 were purified using GST-tagged column purification. A band at 25 
KD and 23 KD were obtained which correspond to PDZ1 and PDZ3 domain, 







Figure 12. Confirmation of ADAM17 coding sequence using restriction enzyme 
double digestion of the vector. 
A band of 3 kbp, corresponding to the expected length of the gene for ADAM17 





Figure 13. Purification of ADAM17 cytoplasmic domain by GST column 
purification. 
The cytoplasmic domain of ADAM17 has MW of 17 KD. Elution 1 and 2 (E1, E2) had 
highly concentrated purified protein. Note that the band intensity decreased as more 
protein is eluted from the GST column. The upper band was mostly likely uncleaved 
GST-ADAM17 or precision protease. E1 and E2 were subsequently incubated with 
GST-beads to remove remnant GST proteins (data not shown). FT, flow through; L&C, 
wash step; ATP, wash step; E1-5, elusions. 
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Immunoprecipitation and Western blot 
Cell cultures were placed on ice for 5 min, washed with ice-cold PBS, and lysed 
in buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, protease inhibitors (20 
µg/ml, leupeptin, aprotinin, 10 µg/ml pepstatin, and 17.4 µg/ml phenylmethylsulfonyl 
fluoride)) by rocking at 4°C for 10 min. Cells were scraped into a tube, sonicated five 
times with 5 pulses using Sonic Dismembrator (Fisher Scientific, model 100) and 
centrifuged at 14,000g for 10 min at 4°C. The supernatant was transferred to fresh tubes 
and subjected to protein estimation by Bio-Rad protein assay according to manufacturer’s 
instructions. Aliquots of each lysate were saved for Western blot analysis of total protein 
in immunoprecipitation (IP) or co-immunoprecipitation (co-IP) experiments. For IP or 
co-IP, an appropriate amount of primary antibody was added to pre-cleared equal protein 
concentration of sample lysate in Eppendorf tubes and rotated at 4°C for 4 hours. Protein 
G Sepharose beads slurry (GE Healthcare) was prepared by washing 3 times with 2X 
volume of lysis buffer and once with lysis buffer minus Triton X-100, followed by 
resuspension in fresh lysis buffer (50% beads + 50% buffer). 50 µL washed beads was 
added to each sample tube with additional rotation at 4°C for overnight. Samples were 
washed 3 times with lysis buffer and once with lysis buffer minus Triton X-100 by 
centrifugation at 17000 rcf, 4°C for 1 min to pellet beads. Each IP sample was 
resuspended in 70-100 µL 2X denaturing buffer with dye (for WB) and incubated in a 
heat block at 65°C with shaking at 300 rpm for 10 min. Samples were then immediately 
vortexed vigorously before spinning at 17000 rcf, 30-60 sec. Only supernatant was 
subjected to SDS polyacrylamide gel electrophoresis (10% unless otherwise indicated). 
Proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, 
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MA), blocked with 5% BSA in TBS-T, washed, probed with appropriate antibody diluted 
in 2% BSA in tris-buffered saline tween-20 (TBS-T) with sodium azide, followed by 
HRP-conjugated secondary antibodies (Jackson Immuno Research, West Grove, PA) 
diluted in TBS-T (1: 10,000). Protein bands were detected by adding ECL reagents 
(Pierce, Rockford, IL) and imaged on a ChemiDocTM MP imaging system (Biorad, CA). 
Cell surface biotinylation 
Cell surface proteins were biotinylated with 3 ml per 100 mm plate of 1 mg/ml 
sulfo-NHS-biotin (Cat # 21331 Thermo Scientific, Rockford, IL) for 1 hour at 4°C after 
first cooling cells on ice for 10 min and washing with ice cold PBS +/+. After washing 
the cells again with PBS +/+, any unreacted biotin was quenched with 100 mM glycine 
for 20 min at 4°C. Washed cells were then incubated with lysis buffer for another 20 min 
at 4°C. Cell lysate was immunoprecipitated with NeutrAvidin ultra link resin (Cat # 
53150 Thermo Scientific) and Western blotting with antibody of interest. 
Adenovirus infection 
Adenovirus serotype 5 containing the β-galactosidase gene (AdV-β-Gal), or AdV-
CAREx7, or AdV-CAREx8 (University of Iowa Vector Core, Iowa City, IA) was diluted 
with Opti-MEM culture media (Gibco, Invitrogen) without serum to the multiplicity of 
infection (MOI) of 100. Growth media was aspirated from cells that had been seeded for 
48 hours and the cells were rinsed with phosphate buffered saline containing Ca+2 and 
Mg+2 ions (PBS+/+). 250 uL of diluted adenovirus was added to each well in a 24 well 
plate (3 ml in 10 cm2 dish) at a MOI of approximately 100 plaque forming units/cell 
(PFU/cell), unless otherwise indicated, and incubated for 1 hr at 37°C and 5% CO2 with 
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gentle swirling every 15 min. The inoculum was then removed, cells were rinsed with 
Opti-MEM, and fresh complete media was added. The cells were then incubated at 37°C, 
5% CO2 until further analysis. 
Quantitative Polymerase Chain Reaction (QPCR) 
The PCR amplification was programmed for 40 cycles at 95ºC for 10 min 
(denaturation), 58ºC for 1 min (annealing), and 60ºC for 1 min. (extension). qPCR was 
performed using SYBR Green with low ROX (Quanta, Gaithersburg, MD; 10µl master 
mix qPCR reaction contained 2μl DNA, 2X reaction buffer with dNTPs, Accusat Taq 
DNA polymerase, MgCl2 ROX reference dye and SYBR green dye that binds specifically 
to dsDNA) in Stratagene's Real Time PCR System (Agilent Technologies) using 
Mx4000p software v5 for data analysis. 
Beta-galactosidase assay 
The Galacto-Light Plus System (Applied Biosystems, USA) was used to analyze 
adenovirus-mediated beta-galactosidase activity according to manufacturer directions. 
Briefly, cells were lysed 24 hours after adenovirus infection. 100 µL of lysis buffer were 
added to each well in a 24-well plate for 10 min at room temperature. Cells were scraped 
and 2 µL of lysate was added into a 96-well plate followed by 120 µL of a 1X Tropix-
Galacton substrate (Applied Biosystems) and 60 min incubation at room temperature. 150 
µL of Tropix accelerator II was then added just before measuring β-galactosidase 
luminescence in Luminometer. Protein concentration was determined by Bradford protein 
estimation according to the manufacturer protocol. The optical density was measured at 
spectrophometer wavelength 595 nm as compared to a set of standard. Each experiment 
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was performed in 3-6 replicates and lysis buffer was used as control. Data was analyzed 
using Prism software (GraphPad, CA). 
Nuclear Fractionation 
Nuclear fractionation was done as previously described (153), with some 
modification. Inducible MDCK- CAREx8 (1*107 cells) were induced with 50 ng/ml of 
Dox for overnight. The next day, cells were treated with either TAT-NET1, TAT-E6 or 
TAT-scramble peptides for 4-5 hrs. By the end of the treatment period, cells were 
transferred into 4 ºC and kept for 10 min, washed with PBS without calcium and 
magnesium 3 times. Cells were lifted using Nelson lifting solution (NaHCO3 4.2 mM, 
glucose 5.6 mM, NaCl 137 mM, KCl 5.4 mM, EDTA 0.5 mM. PH 7.2-7.4). After that, 
cells were pelleted by centrifugation at 880 rpm for 6 min. The pellet was re-suspended in 
50 µl of freshly prepared buffer A (10 mM Hepes, PH 7.9, 10 mM Kcl, 1.5 mM MgCl2, 
0.1 mM EDTA, 0.5mM DTT, 0.5% (v/v) NP-40, 1X protease inhibitor cocktail (Pierce 
Thermo scientific, MA)). Samples were centrifuged at 800 x g for 10 min at 4ºC and the 
supernatant was collected as the cytoplasmic extracts. Then, the pellets were re-
suspended in 50 µl of buffer B (20 mM Hepes, PH 7.9, 400 mM NaCl, 1.5 mM MgCl2, 
0.1 mM EDTA, 5% glycerol, 0.5 mM DTT, 1X protease inhibitor cocktail (Pierce 
Thermo scientific, MA)) in order to extract the nuclear proteins. After incubation for 30 
min on ice, samples were centrifuged at 10,000 x g for 30 min at 4 ºC. The supernatant 
was collected as the nuclear extract. A Bradford assay was done to confirm equal protein 
loading, and samples used immediately for Western blot.       
Preparation and collection of conditioned media 
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For CAREx8 or CAREx7 extracellular domain shedding, 2 x 106 – 4 x 106 inducible 
MDCK (60) cells were seeded per well in 6-well plate. The following day, cells were 
washed with PBS containing calcium and magnesium and induced overnight with 50 
µg/ml Dox. The day after, cells were washed with PBS and treated with Tat-peptides 
(final concentration 100 µM or as indicated in the text) in serum deprived media for 4-5 
hrs. The conditioned media were collected in pre-chilled tubes, cleared of cell debris, and 
rotated at 4ºC for 2 hrs with mouse anti-Flag antibody (Fisher scientific, MA). Protein G 
Sepharose bead slurry (GE Healthcare) was prepared by washing 3 times with opti-MEM 
media, and 40 µL of washed beads was added to each sample tube with additional 
rotation at 4°C for overnight. The next day, beads were precipitated by centrifugation at 
4°C then washed 3 times with Opti-MEM. Finally, precipitate was eluted with 
Laemmli/2-mercaptoethanol buffer and subjected to SDS-polyacrylamide gel 
electrophoresis (10% unless otherwise indicated). Proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA), blocked with 5% 
BSA in TBS-T, probed with rabbit anti-Flag (Millipore, MA) to detect the shed CAR 
ECD. The membrane was also stained with Ponceau S stain to confirm equal loading. 
Preventing AdV infection by the shed CAR ECD 
Conditioned media from vehicle, TAT-scramble, TAT-NET1, or TAT-E6 treated 
MDCK epithelia was collected and incubated with AdV-GFP (MOI 100) for 30 min at 37 
ºC with slight shaking. Hela cells were infected with the mixture for 1 hr after which 
media were replaced with complete media. To remove the CAREx8 ECD, conditioned 
media were pre-cleared using antibody specific for the ECD of CAR (mouse anti-Flag). 
24 hrs post infection, cells were washed with PBS 3 times and images were taken at 20 x 
58 
 
magnification power. Image analysis was done using Metamorph software as previously 
described. 
Ponceau S Stain 
Ponceau S stain (Sigma-Aldrich, MO) was prepared in 0.1% (w/v) in 5% (v/v) 
acetic acid. A PVDF membrane was incubated with Ponceau S stain for 15 min at room 
temp. To destain, the membrane was placed in 10 ml of 10% (v/v) acetic acid solution for 
10 min and scanned for imaging using ChemiDocTM MP imaging system (Bio-Rad, CA). 
RNA extraction 
RNA extraction was done using GeneJET RNA purification kit (Thermo 
scientific, MA), according to the manufacturer protocol. Epithelial cells (5*106) or lung 
tissue (30 mg) were lysed using lysis buffer containing β-mercaptoethanol on ice. The 
lung tissues were homogenized using mortar and pestle in 300 µL until suspension is 
uniform. Once homogenized, proteinase K (600 µl) was added to the mixture and vortex 
then incubated for 10 min at room temperature to insure homogenous solution. Mixture 
was then centrifuged at 4ºC for 10 min at 13,500 x g, and it was transferred to RNA free 
tube. Repeated administration of the lysate (up to 700 µl) was added into RNA 
purification column. Each time, the column was centrifuged at 13,500 x g for 1 min and 
the flow through was discarded. The column was washed twice with wash buffer 1, and 
wash buffer 2. Finally, the RNA was eluted with ribonuclease free water added to the 
center of column. Gloves were change between each steps and aseptic technique were 
taken in consideration to minimize RNA degradation. The RNA was directly used to 
make cDNA for further experiment.  
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Reverse PCR and cDNA synthesis 
Freshly isolated RNA was subjected to cDNA using qSriptTM cDNA SuperMix, 
according to the manufacturer protocol. 1 µg of total RNA was incubated with 1x dilution 
of cDNA supermix in a total volume 20 µl using 0.2 ml micro tubes. After sealing each 
reaction properly, the tubes were vortexed and centrifuged briefly to collect the mixture 
at the bottom of the reaction tube. The mixture was loaded into 96 wells plate and sealed 
with plastic cover. All steps were performed on ice to minimize ice. The PCR setting was 
programmed for 40 cycles 5 min at 25ºC, 30 min at 42ºC, and 5 min at 85 º C, the plate 
was hold at 4ºC. After cDNA was completed, 1/10 of the first strand reactions were used 
for PCR amplification.  
Immunocytochemistry 
Cells were kept on ice for 5 min, washed 3 times with ice cold PBS supplemented 
with Mg2+ and Ca2+ (PBS +/+). The cells were then fixed with methanol containing 1% 
paraformaldehyde for 20 min at -20°C. Cells were rinsed with ice cold PBS, allowed to 
come to room temperature, and blocked with 2% bovine serum albumin (BSA) in 
SuperBlock (Pierce, Rockford, IL) for 45 min. Appropriate primary antibodies were 
added to cells for 2.5 hrs at 37°C or overnight at 4°C. Cells were rinsed 5 times with PBS 
with the last rinse greater than 10 min. Cells were blocked with 2% BSA in Superblock 
for 5 min and then incubated with appropriate Alexa-labeled secondary antibodies 
(Invitrogen) for 2 hrs at 37°C. The cells were rinsed 5 times with PBS and mounted onto 
glass slides using Vectashield mounting media with DAPI (Vector Laboratories Inc., 
Burlingame, CA). Staining was evaluated by laser scanning confocal microscopy 
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(Olympus FV1000) with a 60X oil immersion lens; images are shown as either single X-
Y or X-Z sections. 
Plasmid transfection 
Cells were transfected with plasmids 24 hours after seeding, when cultures 
reached over 60% confluence with Xfect (COS-7) transfection reagent (Clontech). 
Transfected cells were used for immunoprecipitation, Western blot. GFP plasmid was 
transfected into separate wells, under the same conditions with the cloned domains to 
monitor transfection efficiency. All experiments included both positive and negative 
controls, as described in the text, and were repeated a minimum of three times unless 
otherwise indicated. COS7 cells were transfected with the cloned domain plasmids to 
confirm protein expression by immunocytochemistry and Western blotting. MDCK cells 
were transfected using GenJet transfection reagent (SignaGen Laboratories) at the time of 
seeding (reverse transfection) to give 56-60% confluency after 24 hrs.  
SiRNA Transfection 
SiRNA targeting different parts of MAGI-1 gene (StealthTM) were purchased from 
Invitrogen Custom Laboratory Services (Carlsbad, CA) as dry pellets. siRNA that targets 
different parts of ADAM17 gene were purchased from Dharmacon (Lafayette, CO).   
Each siRNA duplex was re-suspended in RNase-free water to make a 20 mM solution.  
siRNA duplex was transfected at the time of cell seeding at concentrations (20-30 µM) 
into MDCK cells (reverse transfection) using Dharmacon transfection reagent I. Cells 
were then seeded with the appropriate number of cells that would give 50-60% 
confluence 24 hours after plating. Cells were incubated at 37°C, 5% CO2 for 48-72 hrs. 
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Non-targeting siRNA sequence (ON-TARGET plus) were used as a control for siRNA 
transfection. Validation of the level of MAGI or ADAM17 knockdown was done by 
evaluation of WB.  
ADAM17 activity assay 
ADAM17 activity was performed as described before with slight modification 
(154). Briefly, 20 µg of protein lysate in assay buffer (50 mM Tris, 5 mM ZnCl2, 150 
mM NaCl, and 10 µg/ml TIMP1, pH 9) was pre-incubated with DMSO or ADAM17 
inhibitor (TIMP3) for 30 min at 37ºC. Then, internally quenched fluorogenic substrate 
Mca-PLAQAV-Dpa-RSSSR-NH2 (Enzo Life Sciences) was added to the mixture (final 
concentration 50 µM) and incubated for 10 min. Fluorescence was measured at an 
excitation of 328 nm and emission of 393 nm using a Synergy H1 microplate reader 
(Biotek, VT). The enzyme activity calculation was done according to the manufacturer 
recommendation. Values were normalized to the protein concentration of each sample.  
Cell polarization and TER measurement 
For polarization studies, 2 x 104 – 2 x 106 cells per well were seeded on 10 mm 
diameter polyester tissue-culture treated Millicell filters with a pore size of 0.4μm 
(Millipore, Bedford, MA). Media on the apical surface of cells was removed the next day 
and the apical surface was maintained dry in order to establish an air-liquid interface. 
Polarized cells actively transport fluid from the apical to the basolateral surface and thus 
maintain a defined apical surface fluid composition. 
Transepithelial electrical resistance was measured with a chopstick ohmmeter 
(World Precision Instruments, Sarasota, FL) every other day (Figure 14). When this 
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measurement was taken, media was aspirated from the wells and replaced with 600 µL 
fresh media at the basolateral surface. 400 µL of PBS supplemented with Ca2+ and Mg2+ 
was applied to the apical surface. The background electrical resistance was determined by 
adding media to the basolateral chamber and PBS to the apical chamber of a blank 
Millicell filter. The TER measurements were recorded in mohm (mΩ). 
FITC Dextran assay 
Assessment of epithelial integrity after peptide treatment was done using FITC-
dextran assay as described before (155). Briefly, primary human airway epithelial cells 
were seeded on millicells and allowed to polarize as described in the TER measurement 
section. FITC-Dextran 4 kD or FITC-Dextran 70 kD (Sigma-Aldrich, MO) were prepared 
as stock solution (10 mg/ml) in ultrapure water and sterilized by filtration through a 0.22 
µM pore size filter. Cells were washed with PBS containing calcium and magnesium, 
from the apical and basolateral side. 150 µl of pre-warmed FITC-Dextran in PBS (final 
concentration= 0.5 mg/ml) were added to the apical surface and 450 µl of PBS were 
added to the basolateral (Figure 14). After incubation for 120 min at 37 ºC, basolateral 
medium was collected, cells were washed with PBS and TER measurement were taken 
again. Controls for this experiment included the calcium chelating agent (EDTA) as well 
as the detergent Triton X-100 treatment for 10 min prior to the FITC-Dextran addition. 
EDTA chelates the calcium required for cadherin based adhesion and transiently breaks 
the junctions. Triton X-100 destroys the epithelial integrity by membrane 
permeabilization and it is used to assess to what extent the tracer molecules bind to 
remaining cellular components and debris (155). TER measurement were taken before 
and after treatments to confirm disruption of the epithelial tight junctions.  
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By the end of the 2 hrs, 100 µl aliquots were taken from the basolateral chamber 
and transferred to a 96-well plate for determination of relative fluorescence intensity 
(RFU) in a pre-calibrated Synergy H1 microplate reader (Biotech, VT) using software 
Gen5 2.04. A standard curve of each FITC-Dextran was established using range of 
concentration 0-20 µg/ml. The RFU values of the standard curve samples were taken in 
triplicates with an excitation wavelength 490 ± 9 nm and an emission wavelength of 520 
± 9 nm. The standard curves were used to determine the unknown concentration of the 





Figure 14. Schematic diagram of methods used to assess epithelial cells integrity. 
(A) Model of TER measurement as an indicator of epithelial polarization. Transepithelial 
electrical resistance (TER) was determined by adding media to the apical and basolateral 
chambers. Electrical resistance was taken in mΩ using voltmeter with chopstick electrodes. 
(B) Schematic model of FITC-Dextran permeability assay across epithelial cells. FITC-
labelled dextran was added to the apical surface. Dextran diffusion was assessed by collecting 
the basolateral media and measuring at the emission fluorescence of the FITC-dextran. 
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FITC-Dextran permeability assay is a good measure of epithelial integrity 
In order to validate my approach in using FITC-Dextran as a measure of epithelial 
integrity, I optimized the conditions of FITC-Dextran assay in epithelia cells. First, 
epithelial cells were polarized on millicells until the TER reaches 1500-3000 Ohm. Then, 
the epithelia were treated with PBS, EDTA or Triton X-100 for 10 min at 37°C.  In no 
treatment or PBS treatment condition, no significant change in the TER detected from 
baseline (Figure 15). In contrast, treatment with EDTA or Triton X-100 significantly 
dropped the TER (Figure 15), indicating that the measured TER was due to the tight 
junctions between epithelial cells. FITC-labelled Dextran permeability is another 
indicator of the epithelial integrity. To study the correlation between FITC-Dextran and 
the emission fluorescence, serial dilutions of standard concentration of the FITC-Dextran 
4 kD and FITC-Dextran 70 kD were prepared. The fluorescence intensity was measured 
and standard curve was created for each Dextran. The standard curve of both FITC-
Dextrans gave straight line with R2=0.99 which indicates a linear correlation between the 
fluorescence intensity and the amount of FITC-Dextran in the solution (Figure 15).  
I used this technology to assess the paracellular Dextran diffusion between 
epithelial cells. The procedure was done as explained above. FITC-Dextran 4 kD was 
used to assess paracellular flux of small molecules whereas Dextran 70 kD was used to 
assess the paracellular movement of large molecules. Under normal conditions (no 
treatment), there is traces of Dextran 4 kD that diffused across the epithelia but much less 
Dextran 70 kD, indicating intact tight junctions of the epithelia. PBS treatment slightly 
increased the diffusion of Dextran 4 kD but not Dextran 70 kD (Figure 15). Interestingly, 
treatment with EDTA (Ca+2 ion chelator) significantly increased the amount of Dextran 4 
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kD only, indicating partial disruption of the adherens junctions (Figure 15). Treatment 
with Triton X-100 significantly increased the diffusion of both Dextrans indicating 
complete perturbation of the cell junctions (cell lysis). This result further validates the 




Figure 15. Optimization of FITC-Dextran permeability assay.  
MDCK Epithelia were polarized and TER measurements were taken after 10 min of 
(A) no treatment (B) treatment with PBS (C) Treatment with 8 mM EDTA or (D) 1 % 
Triton, *p < 0.05 vs baseline. (E) FITC-dextran emission fluorescence correlated with 
the amount of FITC-dextran in solution. Serial dilution of FITC-dextran 4 kD and 
FITC-dextran 70 kD were prepared and excitation-emission fluorescence were 
measured at wavelength 490 ± 9 nm and 520 ± 9, respectively. (F) FITC-dextran 
permeability across polarized epithelial cells seeded on millicells. Cells were not 
treated, treated with PBS, EDTA, or Triton for 10 min at 37°C. *p < 0.05 compared to 
baseline or no treatment. 
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Vesicle trafficking by Rabs 
The Rab Family antibody sampler kit (cell signaling, MA) was used to investigate 
the CAREx8 trafficking pathway. Polarized inducible MDCK cells were induced overnight 
with 500 ng/ml of dox. The next day, cells were incubated with protein synthesis 
inhibitor cycloheximide (100 mg/mL) for 4 h at 15-20°C to accumulate newly 
synthesized CAREx8 in the trans-Golgi network (TGN). By the end of  the 4 hrs, TGN 
cargo was released by incubation at 37°C for 5-15 min (156). By the end of the release 
time, cells were washed with PBS and fixed immediately with 1% PFA in methanol. 
CAREx8 was stained with mouse anti-Flag and Rabs were probed with rabbit anti-Rab Ab. 
In some optimization conditions, FITC-labelled Wheat Germ Agglutinin (WGA) was 
used as a cell marker for the trans-Golgi compartment. Images were taken using FV1000 
confocal microscopy (Olympus, NJ).  
Animal handling and peptide administration 
Animals (Tom/ CC10 and Tom/Spc background, JAX stock # 007576) were 
housed individually (male) or in groups (females) at 22°C under a 12-hour light/12-hour 
dark cycle with ad libitum access to water and standard mouse chow (3.0 kcal/g, 40.6% 
carbohydrate, 5.5% fat, and 22% protein; Harlan Teklad, Madison, WI). All experimental 
protocols were approved by the WSU Animal Care and Use Committee. Animal were 8-
12 weeks old were originally purchased from Jackson laboratory and bred at the 
University of Iowa animal facility. Mice were anesthetized moderately using isoflurane in 
a closed chamber. Once the animal was knocked out, mice were removed quickly from 
the chamber and were held in 60° declined supine position by securing the fore and hind 
paws with the left hand. A sterile P200 pipette was used to deliver a volume of 50 µl in the 
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left nostril of the mouse during inhalation. Mice were given a dose of 500 µM of peptides 
dissolved in a volume of 50 µl of vehicle (PBS) via intranasal administration. Four hrs 
later, mice were infected intranasal (through the right nostril) with AdV-Cre (University 
of Iowa, IA). Virus dose 1.0*108 PFU/50µl. After each intranasal administration, mice 
were held straight for few minutes to assure that all solution was inhaled. Then, they were 
returned to their cages for recovery to allow Cre-recombinase expression. Approximately 
2 days later mice were euthanized by CO2 inhalation. A 10 mm incision was made over 
the trachea of mice to visualize the insertion of tracheal intubation (size 60 - polyethylene 
(PE) tubing; Becton Dickenson and Co., MD, USA). Tube was moved down to the point 
of tracheal bifurcation and slid gently toward the left lung. At the point of left lung 
bifurcation, the distal trachea was tied but not secured along with the tracheal tube using 
(6-0 nylon; Ethicon). The right tracheal biforation was tied and secured. A solution 
contains 50% PBS and 50% tissue freezing media (Thermoscientifc, MA) was infused 
through the intratracheal tube using 20 ml syringe (Fix inflation). Once inflated, the knot 
was secured. Another knot was made in the proximal trachea and below the intubation 
site. The trachea and the left lung were then dissected, wrapped in foil and frozen in dry 
ice for 2 days. The right trachea was cut distal to the knot secured site. One lobe was 
submerged in RNA later (Thermofisher, MA) for RNA isolation. The other two lobes 
were dissected and frozen in liquid nitrogen for 2 hrs before they were transferred to dry 
ice. The left lung and trachea were fixed frozen in Tissue Freezing Medium (TFM) after 
removal of intubation tube. Lung lobes were cut sectioned in 25 micron sections using 
cryostat HM550 (Thermo scientific, MA). Sections were then vapor fixed in a chamber 
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containing 4% paraformaldehyde. After that they were visualized for red and green 
fluorescence expression using FV1000 (Olympus, NJ).  
Statistics 
All statistical analysis was done using Prism software (GraphPad, CA). 
Depending on the experimental condition, a T-test, one way or two-way Analysis of 
Variance (ANOVA) was performed. Tukey post hoc test was used to compare the all 






CHAPTER 3: Investigation of the Effect and Molecular Mechanism of TAT-PDZ1 
Peptides on CAREx8 and Adenovirus Infection 
Rationale 
 Adenovirus (AdV) and coxsackievirus group B (CVB) infections can be severe and life 
threatening and no specific or effective therapeutics currently exist. Understanding the 
mechanisms leading to decreased susceptibility of the airway epithelium to viral infection 
will improve both therapeutic options and patient outcomes in the future. The discovery 
of the regulatory role of MAGI-1 on CAREx8 opened the door toward a clear and easy 
target for controlling AdV infection. CAREx8 contains a PDZ-binding motif that interacts 
with two MAGI-1 PDZ domains, PDZ1 and PDZ3, which regulate CAREx8 levels in 
opposing ways (Figure 8) (63). While an interaction with PDZ3 causes CAREx8 
degradation and reduces AdV infection, interaction with the PDZ1 domain is able to 
rescue CAREx8 from degradation and increase AdV infection (63). This chapter is focused 
on identifying the mechanism behind MAGI-1 PDZ3-mediated CAREx8 downregulation 
using peptide-based molecules that block MAGI-1 PDZ1. The net result is CAREx8 
degradation and the decreased apical AdV infection in polarized cells. Such therapeutics 






Epithelial cells line most organs and form a strong barrier that protects organs 
from incoming microorganisms and environmental factors. My approach was to 
transduce epithelial cells with a peptide-based sequence that would alter CAREx8 level 
and AdV entry. The first challenge was to enhance peptide transduction in epithelial 
cells. Rapid transduction of proteins into cells can be facilitated by cell-permeable 
peptides (CPP; also called cell penetrating peptides and protein transduction domains) 
(115-117). The 11 aa cell permeable HIV-TAT sequence, which is able to facilitates 
peptide internalization, was conjugated to the C-terminal 9 aa sequence of the full length 
CAREx8, to make TAT-CAREx8-9c. While the last four amino acids of the full length 
CAREx8 are the residues responsible for the direct interaction with MAGI-1, the other 
residues provide extra PDZ domain specificity. I hypothesized that the designed peptide 
sequence would compete with the full length CAREx8 for MAGI-1 binding and release 
CAREx8 from MAGI-1 binding and degradation.  
TAT- PDZ binding peptides enter epithelial and non epithelial cells 
In order to test that the TAT-PDZ binding peptides are capable of entering 
polarized epithelial and non-epithelial cells, TAT-CAREx8-9c peptide was synthesized as 
described in the materials and methods (Genscript). The entry of the TAT- peptide into 
CHO (non-polarized cells that do not express endogenous CAR) and MDCK cells (cells 
able to polarize and express endogenous CAR) was confirmed by two approaches. First, 
73 
 
using matrix assisted laser desorption ionization-mass spectrometry (MALDI-MS), TAT-
CAREx8-9c was detected in lysates from treated cells and spiked cell lysate but not lysates 
from untreated cells or cell medium. The synthesized peptide gave a unique and expected 
peak at m/z 2536 in the spectrum from both cell lines (Figure 16). The second approach 
was done by using fluorescently-labelled TAT-CAREx8-9c. Peptides were synthesized 
and conjugated with the red fluorescence protein, Tamra. In both cell lines, the 
fluorescently labelled Tamra- TAT-CAREx8-9c entered virtually all of the cells and 
localized throughout the cytoplasm with a higher density around the ER/golgi (arrow) 
and also, unexpectedly, within the nucleoli (Figure 17). These results validate my 
approach of using the TAT cell permeable peptides to facilitate peptide entry into 




Figure 16. TAT-cell permeable peptides enter non-epithelial and epithelial cells. 
MALDI-TOF analyses of TAT-CAREx8-9c peptides associate with (A) CHO cells 
(non-epithelial) and (B) MDCK epithelia. A peak at m/z 2536 showed in both cell lines 
corresponded to the m/z of TAT-CAREx8-9c. CHO or MDCK were incubated with 
either TAT-CAREx8-9c or vehicle for 1 hr at 37°C. Cell pellets obtained were used for 
MALDI-TOF mass spectrometric analysis as described under Materials and Methods. 




Figure 17. TAT-Cell permeable peptides enter non-epithelial and Slide epithelial 
cells. 
(A) CHO or (B) MDCK cells were treated with either vehicle (PBS) or fluorescently 
labelled TAMRA-TAT-CAREx8-9c. Peptide was detectable within 1 h after incubation 
inside cells. White arrows indicate ER/Golgi region of cell with intense TAMRA (red) 
fluorescence. Confocal 60x oil immersion lens, White line = 10 µm.  
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TAT- PDZ binding peptides perturb CAREx8 MAGI-1 interaction 
Since the full length CAREx8 can interact with both MAGI-1 PDZ1 and PDZ3, I 
tested if the designed TAT-CAREx8-9c would be able to perturb the interaction between 
MAGI-1 and CAREx8 in the epithelial cells. I used immunoprecipitation to reveal the 
physical uncoupling of CAREx8 and MAGI-1 upon treatment with TAT-CAREx8-9c, using 
the advantage of inducible CAREx8 MDCK epithelial cells that express Flag-CAREx8  
(60). As expected, MAGI-1 was co-immunoprecipitated with Flag-CAREx8 in the vehicle 
treatment condition. In contrast, co-immunoprecipitation of MAGI-1 with Flag-CAREx8 
was markedly decreased in MDCK cells pre-treated with TAT-CAREx8-9c. Interestingly, 
pre-treatment with TAT-CAREx8-9c that contains mutated PDZ binding motif (TAT-
CAREx8- AA-9c), did not affect co-immunoprecipitation of MAGI-1 with Flag-CAREx8 
(Figure 18). These results indicate that the TAT-CAREx8-9c peptide, but not the mutated 
peptide, is able to disrupt the cellular interactions between the full length CAREx8 and 





Figure 18. TAT-cell permeable peptides interrupt MAGI-1-CAREx8 interactions. 
Western immunoblots showing immunoprecipitates (IP, left lanes) from inducible 
MDCK-CAREx8 epithelia pretreated with TAT-CAREx8-9c or control TAT-CAREx8-
AA-9c. Stable MDCK-CAREx8 cells were induced with 200 ng/ml Dox for 24 hrs. 
After overnight induction, cells were treated with either TAT-CAREx8-9c or TAT-
CAREx8- AA-9c (100µM). CAREx8 was immunoprecipitated using flag antibody. 
MAGI-1 was blotted to determine co-IP. Note the marked reduction in MAGI-1 
coimmunoprecipitated with Flag-CAREx8 from MDCK pretreated with TAT- CAREx8-
9c. Right lanes show cell lysate with no immunoprecipitation, acting as positive 
controls. Note that there was no difference in CAREx8 protein level in the IP blot 
possibly due to the increased CAREx8 production induced by doxycycline. 
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TAT- PDZ1 peptides binds selectively to MAGI-1 PDZ1  
In order to identify small molecules that could decrease apical CAREx8 protein 
expression, novel cell-permeable peptides that bind the PDZ1 domain of MAGI-1 were 
developed (Table 4). Target sequences were based on published interactions between 
cellular NET1 and viral HPV16 E6 with MAGI-1 PDZ1 (112, 144). I tested the 
specificity of my peptides to MAGI-1 PDZ domains by a fluorescence binding assay. The 
purified PDZ1 and PDZ3 domains were labelled with the Cy3 fluorophore and tested for 
interactions with the synthesized TAT-PDZ peptides. In contrast to TAT-scramble 
peptide which showed no interactions with either PDZ1 or PDZ3 (Table 4), TAT-
CAREx8-9c bound both domains, with higher affinity to PDZ3 than PDZ1 (Table 4). By 
contrast, TAT-NET1 showed an interaction with MAGI-1 PDZ1 (Kd=28 ± 11 nM) but 
not PDZ3 (Kd = N.I, No Interaction) (Figure 19). Similarly, TAT-E6 bound MAGI-1 
PDZ1 (Kd = 15 ± 4 nM) but not PDZ3 (Kd = N.I, No Interaction) (Figure 20).  These 
results indicate the selectivity of the designed TAT-PDZ1 selective peptides, TAT-NET1 





Figure 19. TAT-NET1 binding peptides bind selectively to MAGI-1 PDZ1 
domain. 
Ligand binding assay between TAT-NET1 peptide and purified MAGI-PDZ-1. MAGI-
1 PDZ3 domain was used as a control. TAT-NET1 binds to MAGI-1 PDZ1 (A, B) but 
not PDZ3 (C, D) (TAT-NET1 Kd=28± 11). Double reciprocal plot (B) showed linear 






Figure 20. TAT-E6 binding peptides bind selectively to MAGI-1 PDZ1 domain. 
Ligand binding assay between TAT-E6 and purified MAGI-PDZ-1. MAGI-1 PDZ3 
domain was used as a control. TAT-E6 binds to MAGI-1 PDZ1 (A, B) but not PDZ3 
(C, D) (TAT-E6 Kd=15± 4). Double reciprocal plot (B) showed linear curve indicating 
a single binding site between the ligand and PDZ1 (B) but not PDZ3 domain (D). 
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TAT-PDZ1 selective binding peptides diminish CAREx8 protein levels and suppress 
AdV transduction 
As TAT-PDZ1 peptides interact selectively with the MAGI-1 PDZ1 domain, I 
tested whether the TAT-PDZ1 peptides were able to promote CAREx8 degradation. First, 
I tested the cancer epithelial cell line, MDCK. Treatment with TAT-NET1 or TAT-E6 
significantly decreased the protein level of CAREx8 (Figure 21). To assess the effect of 
TAT-PDZ1 peptides on AdV transduction, MDCK epithelia were treated with vehicle, 
TAT-scramble, TAT-NET1, or TAT-E6. Both TAT-PDZ1 peptides significantly 
decreased AdV transduction compare to vehicle treatment as measured by qPCR for the 
number of AdV DNA genomes (Figure 21). This corresponded to a decrease in Ad-β-gal 
gene expression using the β-galactosidase assay, which indicated reduced viral 
transduction (Figure 21). I further tested the effect of TAT-PDZ1 peptides on CAREx8 in a 
more clinically relevant model, primary human airway epithelia (HAE). Similar to 
MDCK, the level of CAREx8 protein was significantly decreased in the TAT-PDZ1 
treated conditions (Figure 22). This also corresponded to a suppression of AdV entry into 
the HAE (Figure 22). These data suggest that the TAT-PDZ1 peptides could efficiently 
reduce or prevent AdV entry in airway epithelia. I took a further advanced step and tested 
the efficacy of TAT-PDZ1 peptides in epithelia from an animal model of AdV 
pathogenicity. Using epithelial cells from cotton rats (a well-known animal model for 
AdV pathogenesis, (157)) both TAT-PDZ1 decreased the level of CAREx8 protein 
compared to TAT-scramble and control treated conditions (Figure 23). Similar to HAE, 
AdV transduction was significantly suppressed in the TAT-PDZ1 treated conditions 
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(Figure 23). Overall, these data indicate that TAT-PDZ1 binding peptides efficiently and 





Figure 21. TAT-PDZ1 binding peptides decrease CAREx8 protein levels and AdV 
transduction in MDCK epithelia. 
(A) Western Blotting from MDCK epithelia treated with either TAT-scramble or TAT-
PDZ1 peptides (TAT-E6 or TAT-NET1). A marked decrease in CAREx8 protein level 
was seen in the TAT-PDZ1 treated conditions. Actin was used to confirm equal protein 
loading. (B) QPCR of the AdV viral genome showed a significant decrease in AdV 
entry into MDCK epithelia treated with the TAT-E6 or TAT-NET1 as compared to 
control. (C) B-galactosidase activity assay showed a significant suppression of AdV 





Figure 22. TAT-PDZ1 binding peptides decreased CAREx8 protein levels and AdV 
transduction. 
(A) Western Blotting from Human Airway Epithelia (HAE) treated with either TAT-
scramble or TAT-PDZ1 peptides (TAT-E6 or TAT-NET1). A marked decrease in 
CAREx8 protein level was seen in the TAT-PDZ1 treated conditions. Actin was used to 
confirm equal protein loading. (B) QPCR of the AdV viral genome showed a 
significant decrease in AdV entry into HAE treated with the TAT-E6 or TAT-NET1 as 





Figure 23. TAT-PDZ1 binding peptides decreased CAREx8 protein levels and AdV 
transduction in cotton rat epithelia. 
(A) Western Blotting from cotton rat epithelia treated with either TAT-scramble or 
TAT-PDZ1 peptides (TAT-E6 or TAT-NET1). A marked decrease in CAREx8 protein 
level was seen in the TAT-PDZ1 treated conditions. Actin was used to confirm equal 
protein loading. (B) B-galactosidase assay showed a significant suppression of AdV 





TAT-PDZ1 binding peptides decreased CAREx8 by inducing degradation of the 
translated protein 
I next investigated the mechanism by which TAT-PDZ1 peptides decrease 
CAREx8 protein. First, I tested if TAT-PDZ1 alters CAREx8 mRNA levels by qRT-PCR. 
As expected, there was no change in CAREx8 transcript level upon treatment with TAT-
PDZ1 peptides (Figure 24A). I then tested if TAT-PDZ1 peptides alter CAREx8 protein 
degradation. Using the global proteasome and RIP inhibitor (MG-132), the effect of 
TAT-PDZ1 on CAREx8 peptides was completely reversed in the MG-132 pre-treated 
condition (Figure 24B), indicating that TAT-PDZ1 peptides decrease CAREx8 by inducing 





Figure 24. TAT-PDZ1 binding peptides decrease CAREx8 by inducing degradation 
of the translated protein. 
(A) TAT-PDZ1 peptides do not change CAREx8 transcript levels. RT-PCR from TAT-
PDZ1 pre-treated MDCK epithelia. No change in CAREx8 transcript level was seen 
among treated conditions. (B) Western Blotting of TAT-PDZ1 treated peptides in the 
presence or absence of the proteosomal and RIP inhibitor, MG-132. Pre-treatment with 
MG-132 rescued the full length CAREx8 from TAT-PDZ1 induced degradation. 
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Downregulation of CAREx8 protein levels by regulated intramembrane proteolysis 
(RIP)  
To determine whether TAT-PDZ1 peptides exaggerate the normal cellular 
pathways that regulate CAREx8 degradation, I followed the fate of CAREx8 by ICC and 
confocal microscopy. In MDCK epithelia, most CAREx8 is at the apical surface while 
some is distributed in the cytoplasm (Figure 25A, red). Treatment with TAT-PDZ1 
peptides dramatically altered the localization of CAREx8 to nuclear inclusions consistent 
with RIP (Figure 25B, C, red). To determine the nature of the CAREx8 nuclear inclusions 
after TAT-PDZ1 peptide treatment, the cytoplasmic and nuclear fractions were isolated 
from induced MDCK-CAREx8 cells after peptide or control treatment and cell lysis for 
Western blotting. The advantage of using inducible MDCK-CAREx8 cells is because that 
they express CAREx8 tagged with Flag epitope at the N-terminal extracellular domain 
upon induction with Dox (60). In that way, I was able to distinguish CAREx7 from 
CAREx8, which otherwise would have identical extracellular domains. As expected, 
treatment with TAT-PDZ1-binding peptide decreased cytoplasmic CAREx8 as opposed to 
control TAT-scramble and PBS (dilutent) treatments (Figure 26). Moreover, the nuclear 
fraction showed a 14 kD fragment, which corresponds to the expected size of the CAREx8 
C-terminus, only detectable with C-terminal CAREx8 Ab in the TAT-PDZ1 peptide 
treated cells (Figure 26). These results indicate that TAT-PDZ1 peptides target CAREx8 
degradation and I hypothesized that this was by inducing regulated intramembrane 




Figure 25. TAT-PDZ1 binding peptides change the immunolocalization of 
endogenous CAREx8. 
(A) CAREx8 (red) localizes mainly at the apical membrane of MDCK epithelial cells 
(see xz section). (B) Treatment with TAT-NET1 (50µM) or (C) TAT-E6 (50µM) 
causes delocalization of CAREx8 to the nuclear compartment but has minor to no effect 






Figure 26. TAT-PDZ1 binding peptides translocate the CAREx8 cytoplasmic 
domain to the nucleus. 
MDCK CAREx8 cells were induced with 50 ng/ml Dox after which they were treated 
with 100 µM of TAT-Scr, TAT-NET1, or TAT-E6. Immunoblotting from cellular 
fractionation of MDCK epithelia into cytoplasmic and nuclear fractions is shown. 
Treatment with TAT-PDZ1 markedly decreases CAREx8 in the cellular fraction. A 14 
KD band corresponding to the cytoplasmic domain of CAREx8 was present in the 
nuclear fraction in the TAT-PDZ1 treated conditions. Actin (cytoplasmic) and PCRP-
YY1 (nuclear) were used to confirm equal protein loading in the cytoplasmic and 
nuclear fraction, respectively. 
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Considering that most transmembrane proteins undergo RIP by secretases, I tested 
if γ-secretase inhibitor (compound E) would reverse the effect of TAT-PDZ1 peptides. 
Pretreatment with compound E prevented TAT-E6 induced nuclear translocation of the 
cytoplasmic domain of CAREx8 (Figure 27). I confirmed this result by immunoblotting 
which showed a decrease in the 14 KD fragment formed upon pre-treatment with γ-
secretase inhibitor compound E (Figure 28). I further confirmed the effect of comp E on 
reversing TAT-PDZ1 peptide by cellular fractionation of the cytoplasmic and nuclear 
fraction. Pretreatment with comp E resulted in only a partial rescue of the full length 
CAREx8 from TAT-PDZ1 peptide but completely reversed nuclear translocation of the 
cytoplasmic domain of CAREx8 (Figure 29). Notably, some 14 KD band was detectable in 
the cytoplasmic fraction in the comp E pretreated conditions. This indicates that the TAT-
PDZ1 peptides induce RIP of the cytoplasmic domain of CAREx8 by γ-secretase which 
causes the CAREx8 cytoplasmic domain to be translocated to the nucleus. This is 
consistent with a previous report of ripping the mouse CAR protein (homologous to 




Figure 27. Selective gamma-secretase inhibitor (compound E) reverses TAT-E6 
induced nuclear translocation of the cytoplasmic domain of CAREx8. 
(A) CAREx8 cytoplasmic domain is translocated into the nucleus upon TAT-E6 peptide 
treatment. (B) Pre-treatment with comp E reversed the effect of TAT-E6 and rescued 




Figure 28. Selective γ-secretase inhibitor (compound E) reversed TAT-NET1 
induced nuclear translocation of the cytoplasmic domain of CAREx8. 
Western immunoblotting from MDCK epithelia treated with TAT-NET1 in the 
presence or absence of the selective gamma-secretase inhibitor (compound E). Pre-
treatment with comp E decreased cytoplasmic domain formation of CAREx8 (14 KD), 





Figure 29. Selective gamma-secretase inhibitor (compound E) reverses TAT-
PDZ1 induced nuclear translocation of the cytoplasmic domain of CAREx8. 
CAREx8 cytoplasmic domain is translocated into the nucleus upon TAT-E6 and TAT-
NET1 peptide treatment. Pre-treatment with compound E reversed the effect of both 
peptides and rescued the cytoplasmic domain of CAREx8 from nuclear translocation. 
However, it did not rescue the full length CAREx8 from TAT-PDZ1 induced cleavage. 
Note that the 14 KD band detected in the cytoplasmic fraction is expected to be the 
transmembrane and the cytoplasmic domain of CAREx8, however, no difference in 




TAT-PDZ1 peptides induce CAREx8 extracellular domain shedding  
Because the mechanism of RIP is usually preceded by shedding of the 
extracellular domain (ECD), I tested if the widely expressed membrane metalloprotease 
ADAM17 would reverse the effect of TAT-PDZ1 peptides and restore the level of 
CAREx8. First, I used nuclear fractionation to see if inhibition of ADAM17 would rescue 
ripping of CAREx8. Strikingly, treatment with selective ADAM17 inhibitor (TIMP3) 
completely rescued the full length CAREx8 from TAT-PDZ1 induced CAREx8 degradation 
in the cytoplasmic fraction (Figure 30). As was the case with comp E treatments, 
treatment with TIMP3 ablated the nuclear translocation of the cytoplasmic domain of 
CAREx8 (Figure 30A). I further confirmed the role of ADAM17 in TAT-PDZ1 induced 
CAREx8 degradation using siRNA that selectively targeted the ADAM17 sequence. 
Silencing ADAM17 reversed the effect of TAT-E6 on CAREx8 degradation (Figure 30B). 
This revealed that ADAM17 and gamma-secretase are the two enzymes by which TAT-




Figure 30. Silencing ADAM17 reverses TAT-PDZ1-induced CAREx8 degradation. 
(A) Selective ADAM17 inhibitor (TIMP3) completely reversed the effect of TAT-
PDZ1 peptides in both the cytoplasmic and nuclear fractions and rescued the full length 
CAREx8 from degradation. (B) Silencing ADAM17 did not change CAREx8 levels in the 
absence of TAT-PDZ1 peptide, but it completely reversed the effect of TAT-PDZ1 
peptide compared to control siRNA. N-term Ab: antibody that detects CAREx8 N-
terminal domain (Flag). C-term Ab: antibody that detects CAREx8 C-terminal domain 
(5678p). Actin and PCRP-YY1 were used to confirm equal protein loading in the 
cytoplasmic and nuclear fraction, respectively. 
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Since ADAM17 (also known as TACE) is required for the TAT-PDZ1 effect in 
decreasing CAREx8, I tested whether TAT-PDZ1 peptides induced CAREx8 ECD shedding 
in the extracellular media (hereafter called conditioned media). As expected, TAT-E6 
increased Flag- CAREx8 ECD shedding in the conditioned media of inducible MDCK 
cells in a dose dependent manner (Figure 31). This corresponded with a decrease in the 
full length CAREx8 protein expression in the cell lysate (Figure 31). Similarly, TAT-
NET1 increased CAREx8 ECD shedding in the media, which was corresponded to a 





Figure 31. TAT-E6 peptides induce CAREx8 ectodomain shedding. 
TAT-E6 increased CAREx8 ECD shedding in the cell media in a dose dependent 
manner. This was corresponded to a decrease in the full length CAREx8 in cell lysate.  
MDCK CAREx8 stable cells were induced with 50 ng/ml Dox after which they were 
treated with increasing concentrations of TAT-E6 (0-100 µM). N-term AB: antibody 
that detects CAREx8 N-terminal domain (Flag). C-term AB: antibody that detects 





Figure 32. TAT-NET1 peptides induce CAREx8 ectodomain shedding. 
TAT-NET1 increased CAREx8 ECD shedding in the cell media in a dose dependent 
manner. This was corresponded to a decrease in the full length CAREx8 in cell lysate.  
MDCK CAREx8 stable cells were induced with 50 ng/ml Dox after which they were 
treated with increasing concentrations of TAT-NET1 (0-200 µM). N-term AB: 
antibody that detects CAREx8 N-terminal domain (Flag). C-term AB: antibody that 




ADAM17 inhibitor reversed the effect of TAT-PDZ1 peptide and rescued CAREx8 
from degradation 
To test the hypothesis that ADAM17 is responsible for CAREx8 ECD shedding 
induced by TAT-PDZ1 peptides, epithelial cells were pretreated with increasing 
concentration of ADAM17 inhibitor (TAPI-1) followed by treatment with TAT-E6. 
Treatment with TAPI-1 decreased CAREx8 ECD shedding and rescued the full length 
CAREx8 from TAT-PDZ1 mediated degradation (Figure 33). These data suggest that 
ADAM17 is the mediator through which TAT-PDZ1 peptides induce CAREx8 
degradation. 
TAT-PDZ1 peptides increased CAREx8 degradation is time dependent  
I then tested the time course of TAT-PDZ1 action in epithelial cells. Treatment 
with a single dose (50 µM, 1hr) of TAT-E6 induces CAREx8 degradation which was 
terminated after 24 hrs (Figure 34). In the cell media, TAT-E6 increased CAREx8 ECD 
shedding which plateaus at 2-24 hrs post-treatment (Figure 34). This indicates that the 
effect of TAT-PDZ1 peptides on CAREx8 degradation is fast and lasts for 24 hrs. It also 
indicates that the CAREx8 ECD may be quite stable in the media which may imply a long 
lasting protection from AdV infection due to the shed CAREx8 ECD in the culture media 





Figure 33. TAT-PDZ1 peptides induce CAREx8 ectodomain shedding by ADAM17. 
ADAM17 inhibitor (TAPI-1) reversed the effect of TAT-PDZ1 on CAREx8 ECD 
shedding in a dose dependent manner. MDCK cells were induced with 50 ng/ml Dox 






Figure 34. TAT-PDZ1 peptides induce CAREx8 degradation in a time dependent 
manner.  
MDCK-CAREx8 epithelia were induced with 50 ng/ml of Dox for 24 hrs, after which 
Dox was removed. Cells were then treated with 100µM TAT-E6 peptide and cells 
lysed at different time points. (A) Western immunoblotting for CAREx8 protein 
expression in MDCK epithelia over time after single dose of TAT-E6 peptide 
treatment. CAREx8 degradation is time dependent and the effect of TAT-E6 was 
reversed by 24 hrs. (B) Western immunoblotting of CAREx8 ECD in the media after 
single dose of TAT-E6 peptides treated MDCK for different time point. CAREx8 ECD 




TAT-PDZ1 peptides do not induce CAREx7 shedding 
Due to the fact that CAREx7 and CAREx8 share the same transmembrane and extracellular 
domains, it is expected that ADAM17 would also be able to shed CAREx7 upon treatment 
with TAT-PDZ1 peptides. Moreover, CAREx7 has been shown to interact with MAGI-1-
PDZ3 domain (150). To be able to differentiate and track the ECD of CAREx7, I used 
inducible MDCK epithelia that overexpress Flag-CAREx7 upon treatment with Dox (60). 
In the inducible CAREx7 MDCK epithelia, TAT-PDZ1 peptides significantly decreased 
the endogenous protein level of CAREx8 but did not change the protein level of Flag-
CAREx7 (Figure 35). Moreover, there was no change in the CAREx7 ECD shedding in the 
condition media (Figure 35). These data validated the selectivity of the TAT-PDZ1 
peptides in targeting the CAREx8 isoform but not CAREx7.  
TAT PDZ1 peptides do not change ADAM17 activity 
I hypothesized that TAT-PDZ1 peptides would activate ADAM17, which would 
mediate CAREx8 shedding followed by RIP. Using a fluorogenic ADAM17 enzyme assay 
(154), it was shown that there was no significant change in ADAM17 activity upon TAT-
PDZ1 peptide treatment (Figure 36). Ionomycin was used as positive control for 
activating ADAM17 as reported before (159, 160). These data rule out the possibility that 





Figure 35. TAT-PDZ1 peptides do not affect CAREx7 shedding. 
MDCK CAREx8 stable cells were induced with 50 ng/ml Dox after which they were 
treated with increasing concentrations of TAT-E6 (0-100 µM). No change in CAREx7 
cellular level or ECD domain shedding was noticeable. However, CAREx8 protein is 
decreased slightly with increasing doses of the peptides. N-term Ab: antibody that 
detects CAREx8 N-terminal domain (Flag). C-term Ab: antibody that detects CAREx8 C-





Figure 36. TAT-PDZ1 peptides do not change ADAM17 activity. 
Fluorogenic ADAM17 enzyme assay was done as described in the materials and 
methods. Ionomycin was used as a positive control, and selective ADAM17 inhibitor, 
TIMP3, was used as a negative control. No significant change in the enzyme activity 
was observed upon treatment with TAT-PDZ1 peptides, TAT-NET1 or TAT-E6. 
*P<0.05 compare to control.   
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ADAM17 interacts with MAGI-1 PDZ2 domain 
Another possible hypothesis and explanation of the effect of the peptides is that 
ADAM17 interacts with MAGI-1 at the same time as CAREx8. I tested if ADAM17 and 
CAREx8 are present in a complex and whether treatment with TAT-PDZ1 peptides would 
enhance the affinity/interaction between enzyme and substrate. Cells were transfected 
with plasmids encoding empty pcDNA3.1 plasmid, ADAM17, and ADAM17 together 
with each of the isolated myc-tagged PDZ domains of MAGI-1 (PDZ0-5). 
Immunoprecipitation with a myc-tag specific Ab showed that ADAM17 was co-
immunoprecipitated mainly with the MAGI-1 PDZ2 domain (Figure 37). I confirmed 
these interactions using the direct binding assay between the C-terminus of ADAM17 
(TAT-ADAM17-9c) and the purified MAGI-1 PDZ domains. I tested the ability of the 
purified ADAM17 to interact with each MAGI-1 PDZ domain. A high affinity interaction 
(Kd = 35 ± 7nM) was detected between the ADAM17 C-term domain and MAGI-1 
PDZ2 domain (Figure 38). No interactions were detectable between ADAM17 any other 
MAGI-1 PDZ domain by binding assay (data not shown). Therefore, MAGI-1 is an 
essential scaffold protein that can bring ADAM17 and CAREx8 into the same complex. It 
is likely that treatment with TAT-PDZ1 peptide enhances the close proximity between 






Figure 37. ADAM17 interacts with MAGI-1 PDZ2 domain. 
(A) Western immunoblotting showing lysate (top two panels) and immunoprecipitate 
(bottom two panels) of COS7 cells co-transfected with ADAM17 alone or each myc-
tagged MAGI-1 PDZ domain. Transfected cells were immunoprecipitated using myc 
antibody. ADAM17 was mainly co-immunoprecipitated with MAGI-1 PDZ2 domain. 





Figure 38. ADAM17 has high affinity interactions with MAGI-1 PDZ2 domain. 
(A) Direct binding assay between Cy3 PDZ2 and an ADAM17 C-terminal domain 
showed a high affinity interaction with Kd= 35±8 nM. (B) Double reciprocal plots 
showed a linear line demonstrating a single binding site. 
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TAT-ADAM17-9c reversed the effect of TAT-E6 on CAREx8 and AdV infection 
To further validate the ternary complex hypothesis between MAGI-1, ADAM17, 
and CAREx8, TAT-peptides were designed to target the MAGI-1 PDZ2 domain. Due to of 
the high affinity interactions between ADAM17 and MAGI-1 PDZ2 domain, the last 9 aa 
sequence of ADAM17 was synthesized and tagged to TAT (TAT-ADAM17-9c). The 
effect of TAT-ADAM17-9c on rescuing CAREx8 from TAT-E6 mediated degradation was 
tested in MDCK epithelia. Treatment with TAT-ADAM17-9c in the absence of TAT-
PDZ1 peptide did not change the level of CAREx8, However, TAT-ADAM17-9c rescued 
the full length CAREx8 from degradation upon exposure to TAT-E6 in a dose dependent 
manner (Figure 39). These data further confirmed the hypothesis of ADAM17 binding to 





Figure 39. TAT-ADAM17-9c rescues CAREx8 from TAT-PDZ1 induced 
degradation. 
TAT-ADAM17-9c peptides do not change CAREx8 under control (basal) conditions. 
However, it rescues the full length CAREx8 from TAT-E6 induced degradation in a 
dose dependent manner. MDCK epithelia were treated with 50µM TAT-ADAM17-9c 
for 1hr prior to 4hrs treatment with 50µM TAT-E6.   
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MAGI-1 is an important scaffold protein that brings CAREx8 in close proximity to 
ADAM17 
To verify the role of MAGI-1 in mediating the effect of CAREx8 degradation by 
TAT-PDZ1 peptides, I silenced MAGI-1 by specific siRNA and looked for CAREx8 
expression in the absence or in the presence of TAT-PDZ1 peptides. As shown in Figure 
40, the MAGI-1 protein was successfully silenced in both the PBS and the TAT-E6 
treated condition. I had expected a potential increase in CAREx8 proteins upon MAGI-1 
silencing, however, CAREx8 protein expression was not affected by MAGI-1 silencing. As 
expected, CAREx8 protein expression was significantly decreased in the TAT-E6 treated 
conditions and silencing MAGI-1 rescued the full length CAREx8 from TAT-E6 induced 
degradation (Figure 40). This shows that MAGI-1 is an important mediator for CAREx8 
degradation by TAT-E6 and supports the ternary complex hypothesis between MAGI-1, 





Figure 40. Silencing MAGI-1 reverses the effect of TAT-E6 on CAREx8 
degradation. 
SiRNA designed to specifically target MAGI-1 protein were transfected into MDCK 
epithelia for 72 hrs. Epithelia were treated with either PBS or TAT-E6 for 4-5 hrs 
before lysing the cells. 
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CAREx8 shed ECD reduced AdV infection 
It is plausible that the biological significance of the shed CAREx8 ECD is to act as 
protective mechanism against AdV entry. Soluble CAREx8 ECD has been successfully 
used by many authors to prevent AdV and CVB infection in vitro and in vivo (161, 162). 
Conditioned media from Dox-induced MDCK-CAREx8 epithelia treated with TAT-PDZ1 
or scramble peptides was collected and incubated with AdV-GFP before the mixture was 
added to HeLa cells. HeLa cells are non-polarized, express high levels of CAREx7 protein 
that is not susceptible to TAT-PDZ1 peptide, and are readily susceptible to adenovirus 
infection (See material and methods). Conditioned media from TAT-E6 and TAT-NET1, 
but not TAT-scramble exposed cells, significantly reduced GFP expression in AdV-GFP 
infected HeLa cells (Figure 41). To confirm that the decreased AdV transduction was 
mediated by the shed CAREx8 ECD, conditioned media from the assigned treated 
conditions were cleared by immunoprecipitation using Flag antibody prior incubation 
with AdV-GFP. The mixture was transferred to infect HeLa cells, and AdV transduction 
was quantitated based on GFP expression. Interestingly, removal of CAREx8 ECD 
restored AdV infection in HeLa cells and reversed the effect of the TAT-PDZ1 peptides 
in the cell media (Figure 41). These data illustrated that TAT-PDZ1 peptides have an 
indirect long-term therapeutic effect of abolishing AdV by shedding CAREx8 ECD which 
acts as decoys, binding to AdV fiber-knob, to prevent AdV entry. To verify the 
involvement of ADAM17 in the protective CAREx8 ECD shedding, cells were pre-
incubated with either comp E or TIMP3 before treatment with the peptides, and 
conditioned media was collected and tested for its ability to abolish AdV transduction. 
Consistent with only a partial inhibition of RIP of the cytoplasmic domain by gamma-
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secretase, pre-incubation with comp E did not affect AdV transduction. By contrast, the 
ADAM17 inhibitor TIMP3 completely reversed the effect of TAT-PDZ1 peptides and 
restored AdV infection (Figure 41).  
 To further confirm the ability of CAR ECD to abolish AdV infection, CAR-FC 
protein (which is a purified form of CAR ECD) was incubated with different MOI of 
AdV in cell culture media before infecting HeLa cells. Whereas conditioned media from 
cells treated with PBS demonstrated a dose dependent increase in AdV-GFP infection, 
addition of CAR-FC to PSB-pre-incubation media could partially block the increase of 
infection. Conditioned media from cells treated TAT-E6 significantly decreased AdV-
GFP transduction but could be partially overcome by high doses of AdV (MOI 100) 
(Figure 42). Consistent with previous results, ADAM17 inhibition reversed the effect of 
TAT-E6 and restored the AdV infection (Figure 42). This suggests that the shed CAREx8 




Figure 41. Shed CAREx8 Extracellular domain (ECD) decreases AdV infection. 
MDCK-CAREx8 cells were induced with 50 ng/ml Dox O/N. Cells were treated with 
vehicle, TAT-Scr, or TAT-PDZ1 peptide for 4 hrs after which the C.M. were collected, 
precleared, and incubated with AdV-GFP (MOI 100) for 30 min at 37ºC. HeLa cells 
were then infected with the mixture for 1 hr at 37 ºC. (A) GFP-expression in HeLa 
cells infected with AdV-GFP incubated with conditioned media (C.M.) of MDCK cells 
treated with either TAT-Scr or TAT-PDZ1 peptides. Notice the decrease in AdV entry 
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with C.M media from TAT-PDZ1 peptides (first row). Pre-clearing CAREx8 ECD from 
C.M. by IP (second row), restored the AdV infection in HeLa cells. Pretreatment of 
inducible MDCK cells with gamma-secretase inhibitor (Compound E, Comp E; third 
row) did not reverse the effect of TAT-PDZ1 treatment, however, pre-treatment with 
ADAM17 inhibitor (TIMP3; forth row) did reverse the effect of C.M. from TAT-
PDZ1. (B) Quantitation of the GFP expression in HeLa cells. Quantitation was done by 
Metamorph® 24 hrs post infection as described in the materials and methods, *p < 0.05 







Figure 42. CAREx8 ECD decreases AdV infection. 
Stable MDCK CAREx8 cells were induced with 50 ng/ml Dox O/N prior to treatment 
with vehicle, TAT-Scr, TAT-PDZ1-E6 peptide, or a combination of TAT-E6 and 
ADAM17 inhibitor TIMP3, for 4 hrs. Conditioned media (C.M.) was collected, 
precleared, and incubated with AdV-GFP (MOI 100) for 30 min at 37 ºC. HeLa cells 
were then infected with the mixture for 1 hr at 37 ºC. (A) GFP-expression in HeLa 
cells infected with AdV-GFP incubated with C.M. taken from MDCK cells or soluble 
CAR EDC (CAR-Fc, 1 mg/ml). AdV-GFP infection was done at MOI 0, 25, 50, 100. 
(B) Quantitation of GFP expression in HeLa cells infected in (A). Quantitation was 
done by Metamorph® 24 hrs post infection as described in the materials and methods, 
*p < 0.05 compared to PBS. 
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TAT-PDZ1 peptides do not change epithelial integrity 
I tested if TAT-PDZ1 binding peptides alter epithelial integrity by two 
approaches. First, epithelial cells were seeded onto millicells and treated with a 50 µM 
dose of TAT-PDZ1 peptides, TAT-scramble, or vehicle (PBS) every day over a period of 
14 days. Trans-epithelial resistance (TER) measurements were taken every other day to 
determine if TER reading would increase. An increase in TER indicates the formation of 
tight junctions and an epithelium. Continuous treatment with PDZ1 peptides did not alter 
the formation of an epithelium and epithelial integrity as showed by TER measurements 
(Figure 43). The second approach involved measuring the epithelial integrity by a FITC-
dextran diffusion assay. FITC-dextran was added to the apical surface of the epithelia and 
basolateral media collected and measured for FITC-dextran an hour later. No difference 
in the permeability of FITC-Dextran 70 KD was noticed between treated and untreated 
conditions (Figure 44). Similarly, no difference in the diffusion of FITC dextran 4 KD 
(Figure 45A) across the epithelial cells was observed upon TAT-PDZ1 treatment as 
compared to control treatment. To further confirm that this effect was due to intact tight 
junctions, cells were treated with 8 mM EDTA for 10 min, followed by peptide treatment 
and FITC-Dextran 4 KD diffusion assay. As expected, pretreatment with EDTA 
increased FITC-Dextran 4 KD diffusion in all conditions equally (Figure 45). Taken 
together, these data illustrate the safety of the TAT-PDZ1 peptide in reducing AdV 






Figure 43. TAT-PDZ1 peptides do not change Transepithelial resistance. 
HAE cells were treated apically with single dose of PBS, TAT-scramble (50µM; for 
4hrs) or TAT-PDZ1 peptides (50µM; for 4hrs) daily for 14 days. Transepithelial 
resistance (TER) was taken every other day for 14 days. No change in TER was 
noticeable upon treatment with TAT-PDZ1 peptides. Each condition represents the 




Figure 44. TAT-PDZ1 peptides do not change FITC-Dextran 70 KD permeability 
across epithelia. 
HAE cells were treated with single dose of PBS, TAT-scramble (50µM; for 4hrs) or 
TAT-PDZ1 peptides (50µM; for 4hrs) daily for 14 days. FITC-Dextran 70 diffusion 
across treated epithelia in the presence or absence of EDTA. There was no difference 
in Dextran 70 KD diffusion among treatments. FITC-Dextran 70 was added from the 
apical membrane and the diffused Dextran was collected from the basolateral media, 
measured and quantified as described in the material and methods. Assay was 





Figure 45. TAT-PDZ1 peptides do not change FITC-Dextran 4 kD permeability 
across epithelia. 
HAE cells were treated apically with single dose of PBS, TAT-scramble (50µM; for 
4hrs) or TAT-PDZ1 peptides (50µM; for 4hrs) daily for 14 days. FITC-Dextran 4 
diffusion across treated epithelia in the presence or absence of EDTA. There was no 
difference in Dextran 4 kD diffusion among treatments. Pre-treatment with EDTA 
increased Dextran 4 kD permeability in all conditions. FITC-Dextran 4 kD was added 
from the apical membrane and the diffused Dextran was collected from the basolateral 
media, measured and quantified as described in the material and methods. Assay was 






The data presented elucidate new potential therapeutics that protect polarized 
epithelia from AdV infection. The newly proposed MAGI-1 PDZ1 domain blockers 
resulted in decreased CAREx8 and suppression of AdV infection. Moreover, the results 
illustrated the mechanism by which the PDZ1 peptides degrade CAREx8 and decrease 
AdV infection. Regulated intramembrane proteolysis (RIP) was implicated as the 
mechanism involved in decreasing the level of CAREx8 and also induction of extracellular 
domain (ECD) shedding of CAREx8 followed by localization of the cytoplasmic domain 
to the cell nucleus. Furthermore, I described a new novel interaction mechanism between 
ADAM17 and MAGI-1 PDZ2 domain. This interaction can be used to regulate ADAM17 
expression and activity, which can potentially be exploited to treat many disease 
conditions. A model figure of the proposed molecular mechanism of action of TAT-
PDZ1 peptides is shown in (Figure 46). TAT-PDZ1 peptides bind the MAGI-1 PDZ1 
domain, shifting more CAREx8 to interact with MAGI-1 PDZ3 domain. ADAM17, which 
interacts mainly with MAGI-1 PDZ2 domain, cleaves the CAREx8 ECD. The γ- secretase 
then cleaves CAREx8 from the cytoplasmic domain which is translocated to the nucleus. 
CAREx8 extracellular domain is trafficked to the apical membrane where it is shed or 
released to the extracellular compartment and acts as decoys that bind and neutralize 
AdV.  
My data showed that treatment with TAT-PDZ1 peptides but not TAT-PDZ3 (see 
next section) caused cleavage of CAREx8 by ADAM17 (resides in MAGI-1 PDZ2 
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domain). The exact reason for that is not currently known but one possibility is that that 
distance between MAGI-1 PDZ2 and PDZ3 is shorter than that between MAGI-1 PDZ1 
and PDZ2. The three dimensional orientation of each MAGI-1 PDZ domain as well as 
the active site of ADAM17 is also an important factor to consider, especially with the 
presence of the hinge region in the extracellular domain within ADAM17 structure. 
Further experiments needed to clearly elucidate the exact mechanism. My data also 
showed that ADAM17 cleavage is CAREx8 specific and did not affect the level of 
CAREx7. This could be due to the different localization of the two isoforms in polarized 
epithelia. Also the two isoforms differ only in the extreme C-term domain with CAREx7 
contains 13 aa more. This may have caused different mode of interactions between the 
two isoforms and MAGI-1. 
 The mechanism of protection of TAT-PDZ1 against AdV infection is shown in 
another model (Figure 47). In the absence of CAREx8, the airway epithelia are resistant to 
AdV entry (Figure 47A). If CAREx8 is present at the apical surface, it increases AdV 
entry which can accelerate AdV replication by having more AdV per cell (Figure 47B). 
Treatment with TAT-PDZ1 peptides decreased the level of CAREx8 and prevents AdV 
entry thereby protecting the cells from AdV infection (Figure 47C). In addition, the shed 
CAREx8 ECD generated upon TAT-PDZ1 peptides can act as decoys and decrease the 




Figure 46. Schematic of TAT-PDZ1 peptide mediated decrease of AdV entry into 
polarized epithelia.  
TAT-E6 and TAT-NET1 block MAGI-1 PDZ1 shifting CAREx8 to interact with MAGI-
1 PDZ3 domain. ADAM17 interacts with MAGI-1 PDZ2 domain and cleaves CAREx8 
ECD. The shed CAREx8 ECD interacts with and prevents incoming AdV from entry. 
Gamma secretase cleaves the CAREx8 from the cytoplasmic domain region which 





(A) In the absence of CAREx8, epithelia are protected from AdV entry by the tight 
junctions which separate the apical and basolateral membrane. (B) In the presence of 
CAREx8 AdV enters and replicates in the epithelium, which disrupts the adherent and 
the tight junctions. (C) TAT-PDZ1 peptides decrease the number of CAREx8 in the cells 
which decreases the possibility of AdV entry. (D) TAT-PDZ1 peptides also induce 
CAREx8 ECD shedding which acts as a decoy to protect epithelium from AdV infection.  
Figure 47. Model of protective mechanism of the TAT-PDZ1 peptides against AdV 





CHAPTER 4: Investigation of the effect and molecular mechanism of TAT-PDZ3 
peptides on CAREx8 stability and Adenovirus infection 
Rationale 
Many of the steps that regulate the pathway through which newly synthesized 
CAREx8 reaches the apical membrane remain unclear. By contrast, basolateral 
localization of CAREx7 is known to require interactions with the clathrin adaptor proteins 
AP-1A and AP-1B (61, 163).  The discovery of MAGI-1 as a master regulator of CAREx8 
protein levels prompted screening for drug therapeutics that could enhance AdV 
mediated gene therapy by enhancing AdV binding and entry into epithelia. Such 
therapeutics could also be used to diminish the possibility of side effects mediated by 
high AdV dose required for therapeutic gene expression. The interactions between 
CAREx8 and MAGI-1 are mediated by the PDZ binding domain found at the extreme C-
terminus of CAREx8 and the PDZ domains within MAGI-1 that can be modulated by cell 
permeable peptides. 
The Rab family of small G proteins plays an important role in protein trafficking, 
including defining vesicular cargo destined for apical localization (164, 165). Individual 
Rabs can serve as markers for intracellular trafficking (164), which can be used to 
determine the pathway responsible for CAREx8 trafficking. Such knowledge would allow 
us to broaden our strategies by developing therapeutics that target CAREx8 at a specific 
cellular compartment in order to enhance AdV mediated gene therapy. 
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The main objective of this chapter is to test the hypothesis that cell permeable 
peptides that bind the MAGI-1 PDZ3 domain can act as decoys and rescue full length 
CAREx8 from MAGI-1 PDZ3 domain-mediated degradation. Increased CAREx8 at the 
apical surface of polarized human epithelia can potentially enhance AdV-mediated gene 
delivery in patients with genetic and acquired diseases such as cystic fibrosis, chronic 
obstructive pulmonary disease (COPD), and cancer. These peptides might also behave 






TAT-PDZ3 peptides bind selectively to MAGI-1 PDZ3  
We have previously shown that CAREx8 interacts with both the MAGI-1 PDZ3 and PDZ1 
domains, however, CAREx8 has higher affinity for PDZ3 (63). I hypothesized that 
blocking the interactions between both MAGI-1 domains may be equivalent to blocking 
only the PDZ3 domain. To test this hypothesis and to design blockers that are specific for 
MAGI-1 PDZ3, we searched for interacting partners with the MAGI-1 PDZ3 domain, 
and no other MAGI-1 domains. ESAM is a protein that is known to selectively interact 
with only the MAGI-1 PDZ3 domain through its PDZ binding domain (139). The last 9 
amino acids of both CAREx8 and ESAM proteins were synthesized and tagged with TAT 
cell permeable peptides as described in methods and chapter 3. The selectivity of TAT-
CAREx8-9c and TAT-ESAM toward the MAGI-1 PDZ3 domain was tested by direct 
binding assay using purified peptide and Cy3-labeled MAGI-1 PDZ domains. As shown 
in Figure 48, and as expected, TAT-CAREx8-9c interacts with MAGI-1 PDZ1 domain 
(Kd = 23 ± 10 nM), however, it interacts with higher affinity with MAGI-PDZ3 (Kd = 4 
± 2 nM). Both interactions were confirmed to be single point interactions by the double 
reciprocal plot which showed a linear correlation (Figure 48). TAT-ESAM does not 
interact with MAGI-PDZ1 domain (Figure 49) but it interacts with MAGI-1 PDZ3 
domain (Kd = 17 ± 5 nM) (Figure 49). These data show the high affinity binding of the 
TAT-PDZ3 peptides toward MAGI-1 PDZ3 domain.  
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The PDZ binding domain of TAT-CAREx8-9c is required to rescue CAREx8 protein 
from degradation 
In order to test the specificity of TAT-CAREx8-9c toward MAGI-1 induced 
CAREx8 degradation and its effect on AdV transduction, TAT-CAREx8-9c peptides with 
mutated PDZ binding domain (TAT-CAREx8AA-9c) were synthesized. MDCK epithelia 
were treated with either TAT-CAREx8-9c or TAT-CAREx8AA-9c. In contrast to TAT-
CAREx8AA-9c, which did not change the protein level of CAREx8, TAT-CAREx8-9c 
peptides increased CAREx8 compared to control (Figure 50). The increase in CAREx8 
corresponded to an increase in AdV genome transduction (Figure 50) as well as AdV 





Figure 48. TAT-CAREx8-9c binds to both MAGI-1 PDZ1 and PDZ3 domains. 
Ligand binding assay between TAT-CAREx8-9c and the purified MAGI-1 PDZ1 or 
PDZ-3. MAGI-1 PDZ2 domain was used as a control. TAT-CAREx8-9c peptides binds 
to MAGI-1 PDZ1 (A, B; Kd= 23 ±9), and binds PDZ3 with higher affinity (C, D; Kd= 
4± 2). B, D) Double reciprocal plot is linear indicating a single binding site between 





Figure 49. TAT-ESAM, a PDZ3 binding peptide, binds selectively to the MAGI-1 
PDZ3 domain. 
Ligand binding assay between TAT-ESAM and purified MAGI-1 PDZ1 or PDZ-3. 
TAT-ESAM peptide does not bind to MAGI-1 PDZ1 (A, B) but does binds PDZ3 (C, 
D; Kd= 17± 5). Double reciprocal plot shows (B) no curve indicating no binding to 





Figure 50. TAT-CAREx8-9c increases apical CAREx8 and AdV transduction. 
(A) Western blotting of MDCK cells treated with either TAT-CAREx8-9c or control 
TAT-CAREx8AA-9c. A marked increase in CAREx8 protein level was seen in the TAT-
CAREx8-9c treatment but not the mutated peptides. (B) QPCR of the AdV viral genome 
showed a significant increase in the AdV genomic transduction after TAT-CAREx8-9c 
treatment condition as compared to controls. (C) AdV-β-gal assay of MDCK epithelia 
treated with TAT-CAREx8-9c or control peptides. TAT-CAREx8 -9c treatment 
significantly increased the AdV-β-gal transduction compared to control peptide.  
*P<0.05 compared to control or TAT-CAREx8AA-9c.  
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To further confirm that the increased CAREx8 is mainly due to blocking the 
MAGI-1 PDZ3 domain, MDCK epithelia were treated with TAT-ESAM which binds 
solely to MAGI-1 PDZ3. Interestingly, CAREx8 protein level was markedly and similarly 
increased in TAT-CAREx8-9c and TAT-ESAM treated conditions (Figure 51), indicating 
that the effect is mediated by peptides binding to MAGI-1 PDZ3 domain. Consistent with 
the previous data, the increase in CAREx8 corresponded to an increase in the AdV genome 
entry and transduction as measured by AdV-β-gal gene expression (Figure 51). The same 
experimental approach was done in primary HAE and cotton rat epithelial cells (an 
animal model for AdV pathogenicity). In HAE, CAREx8 was increased in TAT-ESAM 
and TAT-CAREx8-9c treated conditions. This corresponded to an increase in AdV entry 
(viral genomes) and transduction (AdV-β-Gal assay) (Figure 52). Consistent with the 
HAE, TAT-PDZ3 peptide treatment also increased CAREx8 protein as well as AdV-β-gal 
transduction in cotton rat epithelium as compared to control peptides (Figure 53). These 
data suggest that TAT-PDZ3 peptides bind MAGI-1 PDZ3 which increases apical 





Figure 51. TAT-CAREx8-9c and TAT-ESAM increase apical CAREx8 and AdV 
transduction. 
(A) Polarized MDCK cells were treated with either TAT-CAREx8-9c or TAT-ESAM 
and subjected to western blotting for CAREx8 protein. Actin was used to confirm equal 
protein loading. (B) QPCR for Ad viral genome showed a significant increase in the 
AdV genomic transduction in the TAT-CAREx8-9c and TAT-ESAM treatment 
condition as compared to control (PBS). (C) AdV-β-gal assay of MDCK epithelia 
treated with TAT-CAREx8-9c, TAT-ESAM, or control peptides.  Both TAT-CAREx8 -9c 
and TAT-ESAM treatment significantly increased the AdV-β-gal transduction 





Figure 52. TAT-CAREx8-9c and TAT-ESAM increase CAREx8 and AdV 
transduction in human airway epithelia (HAE). 
(A) Polarized cotton rats epithelial cells were treated with either TAT-CAREx8-9c or 
TAT-ESAM and subjected to western blotting for CAREx8 protein. Actin was used to 
confirm equal protein loading. (B) QPCR for Ad viral genome showed a significant 
increase in the AdV genomic transduction in the TAT-CAREx8-9c and TAT-ESAM 





Figure 53. TAT-CAREx8-9c and TAT-ESAM increase CAREx8 and AdV 
transduction in cotton rats epithelia. 
(A) Polarized cotton rats epithelial cells were treated with either TAT-CAREx8-9c or 
TAT-ESAM and subjected to western blotting for CAREx8 protein. Actin was used to 
confirm equal protein loading. (B) AdV-β-gal assay of MDCK epithelia treated with 
TAT-CAREx8-9c, TAT-ESAM, or control peptides.  Both TAT-CAREx8 -9c and TAT-
ESAM treatment significantly increased the AdV-β-gal transduction compared to 




TAT-PDZ3 peptides did not change CAREx8 transcript levels  
To confirm that the increase in CAREx8 was post-translational, I then tested if TAT-PDZ3 
peptides increase CAREx8 by promoting CAREx8 gene expression. Treatment with TAT-
CAREx8-9c and TAT-ESAM did not change the transcript level of CAREx8 compared to 
control (Figure 54). Interestingly, pretreatment with the protein synthesis inhibitor (CHX) 
partially reversed the effect of TAT-PDZ3 peptides (Figure 55). These data show that 
TAT-PDZ3 peptides increase CAREx8 levels by interfering with either newly translated 
protein or protein stability.  
CAREx8 degrades rapidly in polarized epithelia 
 In order to determine the effect of TAT-PDZ3 peptides on CAREx8 protein stability, I first 
determined the half-life of CAREx8 protein in the cell. Stable MDCK-Flag-CAREx8 
epithelia were used and CAREx8 protein synthesis was slightly induced by a low dose of 
Dox (50 ng/ml) overnight. Then, Dox-containing media was removed and replaced with 
media containing the protein synthesis inhibitor CHX in order to arrest protein synthesis, 
and the decrease in CAREx8 protein was tracked at different time points by Western blot. 
Using the one exponential decay approach, the half-life of CAREx8 protein was estimated 
to be 4.2 hrs (Figure 56). These data showed the fast turnover rate of CAREx8 protein in 
cells. To determine the effect of TAT-ESAM on CAREx8 stability, I used the same 
approach in the presence or absence of TAT-ESAM. Treatment with TAT-ESAM 
significantly increased the half-life of CAREx8 and caused a right shift of the degradation 
curve of CAREx8 (Figure 57). The experiment was not carried out long enough to clearly 
determine the new half-life; however, estimation suggested that it was extended to 
approximately >100 hours. Although future experiments will be used to evaluate protein 
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Figure 54. TAT-PDZ3 peptides do not change CAREx8 transcript levels. 
RT-PCR specifically for CAREx8 transcripts after treatment with TAT-PDZ3 binding 





Figure 55. TAT-CAREx8-9c and TAT-ESAM-mediated increase of apical CAREx8 
is reduced by the protein synthesis inhibitor cycloheximide (CHX). 
Western immunoblotting of CAREx8 in MDCK epithelia treated with either TAT-
CAREx8 or TAT-ESAM in the presence or absence of the protein synthesis inhibitor 
CHX. Both TAT-PDZ3 binding peptides increase CAREx8 protein level, the effect was 




Figure 56. CAREx8 degrades rapidly in polarized epithelia. 
MDCK cells stably expressing CAREx8 under a doxycycline-inducible promoter were 
induced for different time points. By the end of each induction period, Dox was 
removed and protein synthesis inhibitor (CHX) was used to stop further protein 
synthesis. (A) Western immunoblotting of CAREx8 protein over time. (B) XY plot 
represents the quantitation of the band intensity of CAREx8/actin from (A). The half-life 





Figure 57. TAT-PDZ3 peptides increase the stability of CAREx8 protein. 
(A) Western immunoblotting of CAREx8 protein degradation profile over time in the 
presence or absence of TAT-ESAM. Treatment with TAT-ESAM increases the 
stability of CAREx8 protein. (B) XY plot represents the quantitation of the band 
intensity of CAREx8/actin from (A). TAT-ESAM shifts CAREx8 protein degradation 
profile and increases CAREx8 half-life. 
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TAT-PDZ3 peptides increase CAREx8 protein at the apical membrane and in a 
vesicular pattern within the cytoplasm    
I tracked the change in level and cellular localization of CAREx8 after TAT-PDZ3 
peptide treatment using ICC. Treatment with both peptides showed a dense speckled 
appearance of CAREx8 localized mainly at the apical membrane (Figure 58, see xz view) 
as well as within the cytoplasmic compartment of polarized epithelia (Figure 58). This 






Figure 58. TAT-PDZ3 peptides increase CAREx8 protein at the apical membrane 
and in vesicular pattern within the cytoplasm. 
Immunocytochemistry of polarized MDCK treated with TAT-ESAM or TAT-CAREx8-
9c shows upregulation of the cellular CAREx8 protein level. CAREx8 is localized mainly 
at the apical surface of polarized MDCK cells. After treatment with TAT-ESAM or 
TAT-CAREx8-9c, CAREx8 is upregulated in a vesicular pattern within the apical surface 
and the cytoplasm of treated cells. Red (CAREx8), Green (MAGI-1, a junctional 




Trafficking of apical CAREx8 protein levels via Rabs 
I hypothesized that CAREx8 is trafficked to the apical membrane of polarized 
epithelia via a regulated endosomal pathway. Rabs, small G-proteins that belongs to the 
Ras family, were used to delineate the trafficking pathway through which CAREx8 is 
localized apically. The Rab families of small G proteins play an important role in protein 
trafficking, including defining vesicular cargo destined for distinct localizations within a 
polarized cell, including apical localization (164, 165). They serve as markers for 
intracellular protein trafficking (164). I hypothesized that newly synthesized CAREx8 
could be accumulated in the ER/Golgi by chilling the cells at 15-20ºC for 4 h and then 
released in bulk into the endosomal pathway, and subsequent trafficking followed. My 
first challenge was to determine the optimal cargo accumulation/release time in MDCK 
epithelia. I used inducible MDCK-Flag-CAREx8 cells that were induced with Dox to 
induce CAREx8 expression overnight. Cells were then incubated at 15-20°C for 4 hrs to 
allow newly synthesized CAREx8 to accumulate in the ER and Golgi. Then cells were 
incubated at 37°C at different time points for 5-20 min to allow trafficking towards the 
apical membrane. Fluorescently labelled Wheat Germ Agglutinin (WGA), which binds to 
sialic acid glycosylated molecules, was used as a marker for the plasma membrane as 
well as trans-Golgi apparatus. At early releasing times of 5-10 min, CAREx8 was localized 
mainly at the nuclear compartment, probably due to insufficient releasing time (Figure 
59). However, at 10-15 min, CAREx8 could be seen leaving the ER/Golgi and entering the 
cytoplasm in a vesicular pattern (Figure 59). Given the vesicle-associated distribution at 





Figure 59. The Golgi-ER cargo is released within 15-20 min in MDCK epithelia. 
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ER-
Golgi cargo was accumulated by incubation at 15-20ºC for 4hrs in the presence of 
protein synthesis inhibitor (CHX). To determine the optimal releasing time from the 
cargo, cargo was released at different time points (A) 5 min, (B) 10 min, (C) 15 min, 
and (D) 20 min followed by immunocytochemistry. Red (CAREx8), Green (Wheat 
Germ Agglutinin, WGA, marker for cell membrane and late Golgi apparatus), Blue 
(nucleus, DAPI). 60x oil immersion confocal microscopy, scale bar= 10µm 
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CAREx8 partially co-localized with Rab4, but not Rab5    
Rab4 is a marker for recycling endosomes within the apical sorting compartment 
whereas Rab5 is a marker for the clathrin coated vesicles and acts as a sorting signal to 
the basolateral membrane. Data showed that CAREx8 partially co-localized with Rab4 but 
not with Rab5 (Figure 60). This is consistent with the apical trafficking of CAREx8 in 
polarized airway epithelia and suggests that CAREx8 may alternate between the apical 
membrane and recycling endosomes in polarized epithelia. 
CAREx8 does not co-localize with Rab7 but partially co-localizes with Rab9  
Both Rab7 and Rab9 are late endosomal markers. Rab7 goes to the lysosome to 
deliver proteins destined to be degraded by the lysosomal pathway. However, Rab9 
marks the vesicles that are recycled from the late endosome back to the Golgi apparatus. 
Results showed that Rab7 does not co-localize with CAREx8 (Figure 61). Consistent with 
the proposed mechanism of CAREx8 degradation, these data show that lysosomal 
degradation is not the main pathway for CAREx8 degradation. However, there was a 
partial co-localization between Rab9 and CAREx8 (Figure 62), indicating that some 





Figure 60. CAREx8 partially co-localizes with the Rab4, recycling endosomal 
marker, but not Rab5. 
Polarized MDCK epithelia were induced with 500 ng/ml Dox overnight. ER-Golgi 
cargo was accumulated by incubation at 15-20ºC for 4hrs in the presence of CHX and 
release by incubation at 37°C for 15-20 min followed by fixation and 
immunocytochemistry. Red (CAREx8), Green (Rab4 or Rab5), Blue (nucleus, DAPI). 
White arrow (inset) shows co-localization between CAREx8 and Rab4 shown in 





Figure 61. CAREx8 does not co-localize with Rab7, a late endosomal marker. 
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ER-
Golgi cargo was accumulated by incubation at 15-20ºC for 4 hrs in the presence of 
CHX and it was released by incubation at 37°C for 15-20 min. CAREx8 did not co-
localize with Rab7, a late endosomal marker. This suggests that newly synthesized 
CAREx8 does not go to degradation pathway. Red (CAREx8), Green (Rab7), Blue 






Figure 62. CAREx8 partially co-localized with the Rab9, late Endosomal-Golgi 
recycling marker. 
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ER-
Golgi cargo was accumulated by incubation at 15-20ºC for 4 hrs in the presence of 
CHX and it was released by incubation at 37°C for 15-20 min. Red (CAREx8), Green 
(Rab9), Blue (nucleus, DAPI). White arrow (inset) show colocalization between 
CAREx8 and Rab9 shown in yellow/orange. 60x oil immersion confocal microscopy, 
scale bar= 10µm 
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CAREx8 almost totally co-localized with Rab11, an early endosomal marker 
 One of the most significant co-localizations observed was between CAREx8 and Rab11, 
an early endosomal marker (Figure 63). The early endosome is an important 
compartment that receives and sorts vesicles from the Golgi, recycling endosome, and 
plasma membrane. Overall, these data showed that CAREx8 is trafficked through three 
main pathways: 1) From the ER-Golgi to the early endosome and/or to the recycling 
endosome. 2) From early endosome to late endosome or to recycling endosome. 3) From 
the late endosome to back to Golgi apparatus. Future experiments will test additional later 




Figure 63. CAREx8 almost totally co-localized with the Rab11, an early endosomal 
marker. 
Polarized MDCK-CAREx8 epithelia were induced with 500 ng/ml Dox overnight. ER-
Golgi cargo was accumulated by incubation at 15-20ºC for 4 hrs in the presence of 
CHX and it was released by incubation at 37°C for 15-20 min. Localization is 
consistent with ICC of CAREx8 at the sub-apical membrane of polarized epithelia. Red 
(CAREx8), Green (Rab11), Blue (nucleus, DAPI). White arrows (inset) show co-
localization between CAREx8 and Rab11 shown in yellow. 60x oil immersion confocal 
microscopy, scale bar=10µm 
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TAT-PDZ3 peptides do not change epithelial integrity 
I tested if TAT-PDZ3 binding peptides alter epithelial integrity by two 
approaches. First, polarized epithelial cells were treated with a dose of 50 µM of TAT-
PDZ3 peptides, TAT-scramble, or vehicle (PBS) daily over a period of 16 days. Trans-
epithelial resistance (TER) measurements were taken every other day. Continuous 
treatment with TAT-PDZ3 peptides did not alter the transepithelial integrity as shown by 
TER measurements (Figure 64). The second approach involves measuring the epithelial 
integrity by FITC-dextran diffusion assay. Consistent with TER data, no difference in the 
diffusion of FITC dextran 70 kD FITC-Dextran diffusion assay showed no change in the 
permeability of 70 kD Dextran permeability between treated and untreated conditions 
(Figure 66).  Similarly, no difference in FITC Dextran 4 kD permeability was seen 
between the treatment conditions after 14 days of continuous treatment (Figure 65). To 
further confirm that the limited FITC-dextran diffusion effect was due to the formation 
tight junctions, cells were treated with EDTA for 10 min, followed by FITC-Dextran 4 
kD diffusion assay. As expected, pretreatment with EDTA increased FITC-Dextran 4 kD 
diffusion in all conditions equally (Figure 66). This illustrates that TAT-PDZ3 peptides 






Figure 64. TAT-PDZ3 peptides do not change epithelial integrity. 
HAE cells were treated apically with single dose of PBS, TAT-scramble or TAT-PDZ3 
peptides (50µM; for 4hrs) daily for 16 days. Transepithelial resistance (TER) was 
measured every other day for 16 days. No change in TER was noticeable upon 






Figure 65. TAT-PDZ3 peptides do not change epithelial integrity. 
HAE cells were treated apically with a single dose of PBS, TAT-scramble (50µM; for 
4hrs) or TAT-PDZ3 peptides (50µM; for 4hrs) daily for 14 days. There was no 
difference in FITC-Dextran 70 kD diffusion across treated epithelia among treatments. 
FITC-Dextran 70 kD was added to the apical membrane compartment and Dextran in 
the basolateral media was measured and quantified as described in the material and 




Figure 66. TAT-PDZ3 peptides do not change epithelial integrity. 
HAE cells were treated apically with a single dose of PBS, TAT-scramble (50µM; for 
4hrs) or TAT-PDZ3 peptides (50µM; for 4hrs) daily for 14 days. (A) FITC-Dextran 4 
kD diffusion across treated epithelia in the absence of EDTA. There was no difference 
in Dextran 4 kD diffusion among treatments. (B) Pre-treatment with EDTA increased 
Dextran 4 kD permeability in all conditions. FITC-Dextran 4 kD was added to the 
apical membrane compartment and Dextran present in the basolateral media was 
measured and quantified as described in the material and methods. Assay performed on 




The presented data validate new potential therapeutics that can be used to promote 
AdV-mediated gene therapy. Results illustrate the mechanism by which the PDZ3 
peptides promote CAREx8 protein and increase AdV infection. My data showed that 
CAREx8 and AdV were increased upon TAT-PDZ3 peptide treatment in three different 
cell lines, including well-differentiated primary airway epithelia. This illustrates the 
reproducibility as well as the widespread application of TAT-PDZ3 peptides in 
promoting AdV transduction and enhancing AdV mediated gene therapy. I also 
discovered a possible mechanism of TAT-PDZ3 peptide action. The mechanism involved 
increasing CAREx8 stability by reducing MAGI-1 mediated CAREx8 degradation. 
However, the exact mechanism is yet to be fully elucidated. In addition, I have shown 
that there was right shift in the CAREx8 degradation curve in the TAT-ESAM treated 
condition; suggesting an increase in the half-life of CAREx8 protein. Further studies are 
needed to determine the fold increase in CAREx8 stability upon TAT-PDZ3 peptides 
treatment. Moreover, the proposed work illustrated possible trafficking pathways of 
CAREx8 to the apical membrane of polarized epithelia. Although further studies are 
needed, CAREx8 is suggested to be recycled between three main pathways. First, from the 
ER-Golgi to the early endosome and/or to the recycling endosome. Second, from early 
endosome to late endosome or to recycling endosome, and finally, from the late 
endosome to back to Golgi apparatus.  The significance of the data in this chapter is that 
TAT-PDZ3 peptides can be exploited to enhance AdV mediated gene therapy by 
overexpression of CAREx8 in order to treat a wide variety of genetic diseases and 
disorders such as cystic fibrosis (Figure 67). It is also can be used to decrease the possible 
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side effects by lowering the viral load given to a patient in current clinical trials where 





Figure 67. Model of enhancing AdV mediated gene therapy in cystic fibrosis (CF) 
epithelium by TAT-PDZ3 peptides. 
(A) In the absence of CAREx8, CF epithelia are devoid of the CFTR protein and 
resistant to AdV-CFTR transduction due to low levels of apical CAREx8. (B) In the 
presence of TAT-PDZ3 peptides, CAREx8 level is significantly increase which would 
enhance AdV-CFTR transduction and (C) restore CFTR in the CF epithelium. CF: 




CHAPTER 5: Biological evaluation of the effect of MAGI-1 TAT-PDZ peptides on 
Adenovirus infection in vivo 
Rationale 
AdV infection is common and can be life threatening (7). Currently there are no 
specific therapies to prevent or treat AdV infections and supportive care is the most 
common intervention. On the other hand, AdV remains the most commonly used vector 
for gene therapy (29). The objective of this chapter is the evaluation of a novel strategy to 
decrease or increase airway epithelial apical CAREx8 in order to decrease or increase AdV 
infection in vivo, respectively. My overall hypothesis is that decreasing apical CAREx8 
will decrease AdV infection by decreasing viral entry while increasing CAREx8 in cells 
can be used to enhance the efficacy of AdV mediated gene therapy.  
The lung is an initial portal for infection by many wild type AdV, such as AdV5, 
and is also a major target for gene therapy. Recombinant AdV-mediated gene delivery to 
the airway of mice via intranasal (IN) administration has been well studied (166-169). 
Low level AdV transduction in the lungs can be overcome by very high viral inoculums 
(~1010 IU) which can be lethal and causes profound side effects (44).  
  In the previous chapters, I demonstrated that cell permeable peptides that disrupt 
CAREx8 interactions with MAGI-1 were able to modulate CAREx8 levels and AdV 
transduction in vitro. In this chapter, I used the novel transgenic mouse model “td-
Tomato” and recombinant AdV that carries cre-recombinase gene (AdV-Cre) to test the 






To test the effect of the TAT-PDZ peptides on AdV infection in vivo, transgenic 
mice td-Tomato (JAX stock # 007576) were used. All mouse cells have a double 
fluorescent Cre reporter gene that expresses membrane-targeted tandem Tomato (tdT, 
RFP variant) prior to Cre mediated excision (lox p) and membrane-targeted green 
fluorescent protein (mG) after excision (170). That is, upon cre- recombinase expression, 
RFP-expressing cells will be converted to GFP-expressing cells (Figure 68). The genetic 
change is permanent and allows AdV transduction to be quantified based on the cell-by-







Figure 68. Red-tomato mice tdT-mouse model. 
All cells express a transmembrane-bound form of RFP and fluoresce red. Upon expression 
of Cre re-combinase via AdV5-Cre, the tdT gene is cut out allowing transcription and 




TAT-PDZ1 peptides suppressed AdV entry whereas TAT-PDZ3 promoted AdV 
transduction in lung tissue 
Mice were anesthetized moderately by isoflurane after which they were treated 
intranasally (IN) with vehicle (PBS), TAT-CAREx8-AA-9c, TAT-PDZ1 (TAT-NET1), or 
TAT-PDZ3 (TAT-CAREx8-9c or TAT-ESAM) for 4 hrs. After which they were infected 
IN with AdV-Cre and 48 hrs later, lung tissues were investigated for GFP expression. As 
shown in Figure 69A, animals receiving no virus showed only RFP without GFP 
expression. Vehicle treated mice showed uniform distribution of the number of infected 
cells (shown in green) among the lung sections. Pre-treatment with TAT-PDZ1 peptides 
decreased the number of infected cells in contrast to TAT-PDZ3 peptides which 
increased the number of GFP infected cells. Quantitation of the number of GFP 
expressing cells showed a significant increase in TAT-PDZ3 treated mice and a decrease 
in TAT-PDZ1 treated mice (Figure 70). Similarly, the ratio between GFP to RFP 
intensity showed a similar trend of increased and decreased infection in TAT-PDZ3 and 





Figure 69. MAGI-1 PDZ1 binding peptides decrease AdV5-Cre infection whereas 
PDZ3 binding peptides increase AdV5-Cre infection in vivo. 
Analysis of lung cryosections from tdT mice pretreated with A) No virus, B) Control 
(PBS or TAT-CAREx8-9cAA), C) PDZ1 TAT-NET1 binding peptide, or D) PDZ3 
TAT-ESAM binding peptide 4 h prior to AdV5-Cre intranasal infection. 20x confocal 





Figure 70. MAGI-1 PDZ1 binding peptides decrease AdV5-Cre infection whereas 
MAGI-1 PDZ3 binding peptides increase AdV5-Cre infection in vivo. 
Quantitative analysis of GFP expression in lung cryosections from tdT mice with no 
virus, pre-treated with control, PDZ3 TAT-ESAM peptides, or PDZ1 TAT-NET1 
peptides.  (A) Total GFP expressing cells counted in lung sections from different 
treatment conditions. (B) Quantification of total GFP/Total RFP fluorescence in lung 
section of different treated conditions by image J. There is significantly higher or lower 
GFP expression in TAT-ESAM or TAT-NET1 treated mice, respectively. Data are 
average of quantification from 10 sections. * P<0.05 compare to control 
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TAT-PDZ1 peptides decrease viral genomes whereas TAT-PDZ3 increased viral 
genomes in lung tissue of td-Tomato mice 
 I further confirmed the change in AdV-Cre transduction in the lungs of td-Tomato mice 
by quantitation of the GFP expression. GFP mRNA was first extracted from lung sections 
of treated mice, then cDNA was synthesized as described in the material and methods. 
Data were normalized to control. QPCR of the synthesized DNA showed a significant 
increase in GFP expression in TAT-ESAM treated mice as compared to control. 
Moreover, TAT-NET1 treated mice showed significantly less GFP expression compared 
to control (Figure 71). To further confirm that the formed GFP was due to change in 
AdV-Cre transduction in the lung epithelia, AdV genomic copies were assessed by qPCR 
of the viral genome. As expected, TAT-ESAM treated mice had increased viral genome 
copies in their lung tissue compared to control while TAT-NET1 treated mice had 
significantly decreased AdV genome copies in their lungs (Figure 71). These results 
showed the efficacy of TAT-PDZ peptide in altering AdV transduction in vivo and 
validate the use TAT-PDZ1 peptides as prophylactic treatment against AdV infection and 




Figure 71. MAGI-1 PDZ1 binding peptides decrease AdV5-Cre infection whereas 
MAGI-1 PDZ3 binding peptides increase AdV5-Cre infection in vivo. 
(A) RT-PCR for GFP mRNA expression after isolation of total RNA from lung tissue 
of control or peptide treated mice. (B) QPCR of viral genome copies in lung tissue 
from control or peptide treated mice. There is a significant increase or decrease of GFP 
expression as well as viral genome copies in lung tissue from TAT-PDZ3 or TAT-




In this chapter, I have performed pre-clinical evaluation of new potential 
therapeutics that alters AdV infection in vivo. By using a novel transgenic td-Tomato 
mouse model, TAT-PDZ binding peptides showed promising outcomes that can be used 
to either promote AdV mediate gene therapy or as prophylactic treatment against AdV 
infection in vivo. The advantage of using the td-Tomato mouse model is the non-invasive 
and easy assessment of the efficacy of TAT-PDZ peptides in vivo. TAT-PDZ1 peptides 
treatment lowered the number of AdV-Cre infected cells as well as AdV genome whereas 
TAT-PDZ3 peptides increased the AdV-Cre transduction. One shortage of the in vivo 
work was the relatively small N (N= 2-3). Nevertheless, more studies need to be done 
with a larger “n/group” to further elucidate the safety and effectiveness of the TAT-PDZ 
peptides in vivo. Future work will also focus on pathogenesis studies and gene therapy 














CHAPTER 6: Discussion 
We have shown for the first time that AdV transduction can be modulated by 
targeting the apically localized CAR isoform using cell permeable peptides that interrupt 
MAGI-1-CAREx8 interactions. We were able to dissect the mechanism by which MAGI-1 
triggers CAREx8 degradation. TAT-PDZ1 binding peptides showed decreased CAREx8 and 
AdV infection in cancer epithelial cell lined, primary human airway epithelia, and 
epithelia from animal models of AdV pathogenicity (cotton rats), and in vivo. Together 
this reveals a novel mechanism for prophylactic therapeutics that can reduce AdV entry 
and infection of populations susceptible to AdV infection. Moreover, we used a similar 
approach to develop therapeutics that would enhance AdV entry. By using TAT-PDZ3 
binding peptides that block MAGI-1 PDZ3 domain, we were able to increase the apical 
CAREx8 levels and enhance AdV entry in vitro and in vivo. This suggests the application 
of these peptides as potential therapeutics to enhance AdV mediated gene therapy.  
I showed that MAGI-1 mediates a ternary interaction between ADAM17 and 
CAREx8 through its PDZ domains and that TAT-PDZ1 peptides mediate their effect by 
blocking interactions with the MAGI-1 PDZ1 domain. I validated the selectivity of the 
peptides to the corresponding PDZ domain by a direct binding assay. Furthermore, I 
showed that MAGI-1 is a main mediator in this pathway and that silencing MAGI-1 can 
reverse the effect of the TAT peptides on CAREx8. However, taking in consideration the 
structural similarity between PDZ domains, as well as the fact that CAREx8 interacts with 
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many PDZ domain containing proteins (47, 102-105), it is possible that these peptides 
can bind and block other cellular PDZ domains. It is unknown how such off-target effects 
might affect the level of CAREx8, however, I have shown the TAT-PDZ peptides do not 
change epithelial cell integrity, which rules out any possible overt toxicity from such 
potential off-target effects (if present) and suggests these peptides may be safe.  
My data also showed that TAT-PDZ peptides indirectly targeting the nascent 
translated protein of CAREx8. This was supported by the fact that the effect of the TAT-
PDZ peptides was reversed upon inhibition the protein translation. Moreover, the 
peptides effect was worn off after 24 hrs of treatment suggesting a reversible effect. 
Furthermore, there was no change in the level of MAGI-1 protein upon treatment with 
TAT-PDZ peptides which proved that TAT-PDZ peptides are transiently disrupting the 
interaction between CAREx8 and MAGI-1 PDZ domains. Together, these data suggest a 
safe and reliable therapeutic approach for regulating the susceptibility of epithelia to AdV 
infection. 
We and others were able to detect CAR expression at the apical membrane of 
epithelial cells (45, 61, 171). It is believed that the newly discovered TAT-PDZ1 binding 
peptides can abolish AdV entry by two phases. The first phase, acute phase, involves a 
decrease in the apical membrane-associated CAREx8 protein level which diminished the 
AdV entry due to a reduction in available receptor. This phase take place during the early 
time of TAT-PDZ1 peptide treatment that causes a shift of CAREx8 binding with the 
savior domain of MAGI-1, PDZ1, to the degradation domain, PDZ3. This shift causes a 
transient but significant decrease in the membrane level of CAREx8 and AdV entry. The 
second phase, chronic phase, is initiated by the shed CAREx8 ECD, providing long-term 
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protection against AdV infection. This happened when CAREx8 bound to MAGI-1 PDZ3 
domain becomes increasingly a substrate available for ADAM17. The resulting cleaved 
ECD is secreted outside the cells and acts as decoy that binds AdV outside of the cell and 
protects the epithelia from further AdV entry. I speculate that it may also act as a 
scavenger for the nascent replicating AdV inside epithelial cells.  
My data suggests that ADAM17 is responsible for CAREx8 but not CAREx7 
shedding which is triggered by PDZ1 binding peptides. It is possible for ADAM10, 
which has the closest homology with ADAM17, to be a candidate for CAREx8 shedding 
(158). However, ADAM17 involvement in CAREx8 degradation is more likely for several 
reasons. First, ADAM10 is involved in constitutive shedding (172) whereas ADAM17 is 
involved in stimulated shedding (173). Second, in epithelial cells, ADAM10 has been 
shown to be localized at the basolateral surface (174), in contrast, ADAM17 sequestered 
mainly in the lipid rafts (175, 176), which is consistent with being localized at the apical 
membrane in polarized epithelia (177). Third, the C-term domain of ADAM17 (-ETEC) 
contains a class I PDZ binding motif, which enables ADAM17 to interact with PDZ 
domain containing proteins (178, 179), while ADAM10 C-term domain lacks such a 
sequence (-HMRR).  
 It is also worth noting that CAREx7 (which has identical transmembrane and extracellular 
domains as CAREx8) interacts with the third PDZ domain of MAGI-1 (150).  However, 
the level of CAREx7 was not affected by treatment with TAT-PDZ1 peptides. There are 
many possible explanations for why that happens. One of the most plausible reasons is 
different sorting between the two isoforms in the polarized epithelia. In polarized airway 
epithelia, CAREx8 is localized at the apical membrane whereas CAREx7 is localized at the 
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basolateral membrane (45, 163). Therefore, it is predicted that ADAM17 is localized with 
CAREx8 at the apical surface (175, 176), whereas ADAM10 is localized at the basolateral 
membrane and if there was an interaction, ADAM10 would be responsible for CAREx7 
shedding (174). This hypothesis can be tested by testing the effect of ADAM17 on 
CAREx7 in non-polarized cell lines. Another possibility is that CAREx7 has 13 amino acids 
more than CAREx8 at the C-term domain. This could cause a shift of the ADAM17 
cleavage site within CAREx8 ECD. Such shift in the cleavage site may render CAREx7 
inaccessible to cleavage by ADAM17. One possibility to test this hypothesis is by 
replacing the CAREx7 cytoplasmic domain (including the PDZ binding motif) with that on 
CAREx8 or alternatively by deletion some from CAREx7 to make the full length same size 
as CAREx8. Finally, it is possible that each isoform is associated with a different family of 
proteins due to the difference in the extreme C-term domains, which render CAREx8 but 
not CAREx7 accessible for cleavage by ADAM17.    
ADAM17, but not ADAM10, has a PDZ binding motif and interacts with the 
third PDZ domain of another cellular PDZ-domain containing protein Dlg/SAP97 (178, 
179). Interestingly, this interaction plays important role in the regulation ADAM17 
activity. Disruption the ADAM17 interaction with the SAP97 PDZ domain significantly 
increased epidermal growth factor receptor (EGFR) shedding by ADAM17 into the cell 
media (178). If this is true, it would mean that ADAM17 activity can be regulated by 
interfering with its interactions with the PDZ domain. This strategy can be used to 
increase ADAM17 activity in conditions where ADAM17 is a potential therapeutic 
target. My data showed that blocking the ADAM17 interaction with MAGI-1 PDZ2 
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domain via TAT-PDZ2 targeted peptides reversed the degradation of CAREx8, although I 
do not have evidence on how would that change ADAM17 activity. 
MAGI-1 is a widely expressed scaffold protein in the body. Data from our lab has 
suggested that MAGI-1 is part of the endoplasmic reticulum associated degradation 
(ERAD). ERAD is a quality control mechanism that can target transmembrane proteins to 
the degradation pathway. The discovery that ADAM17 interacts with MAGI-1 is a novel 
finding and may link MAGI-1 mediated degradation to other associated proteins. This 
new finding can potentially explain the mechanism behind degradation of other MAGI-1 
interacting proteins. For example, Delta-like ligand (Dll), which plays important role in 
cell communication and cell division, interacts with the fourth PDZ domain of MAGI-1 
(180), and is known to undergo cleavage by ADAMs and secretases (181).  
My data showed that silencing ADAM17 reversed the effect of TAT-PDZ1 
peptides on CAREx8 degradation, nevertheless, many bands of CAREx8 were detected only 
in the ADAM17 silencing condition. The exact reason for these bands is still unknown 
but it is possible that silencing ADAM17 makes CAREx8 susceptible to post-translational 
modifications such as ubiquitination. Another strong hypothesis is that ADAM17 could 
be important for the proper glycosylation and folding of the full length CAREx8 (182). 
The actual molecular wt of CAREx8 is 38 KD but it runs at 46 KD on a SDS-PAGE gel. 
The is due to glycosylation of the extracellular domain of CAREx8. It has been shown that 
glycosylation is necessary for the proper folding and for the functional effect of CAR 
(182). Therefore, the non-glycosylated CAREx8 is considered misfolded and it is trapped 
in the ER until it is fully glycosylated. The multiple bands of CAREx8 that appeared upon 
ADAM17 silencing could be the non- or partially-glycosylated forms of CAR. If this is 
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true, that would mean that ADAM17 acts as scavenger that degrades the non-functional 
forms of CAREx8, which can be novel new role for the ADAM17 enzyme.     
Several studies have shown that administration of “soluble CAR” ectodomain 
(sCAR) is a potential antiviral strategy for both wildtype AdV and CVB infection (162, 
183, 184), however, systemic administration of the sCAR is immunogenic and can 
aggravate heart failure (184). Our approach is unique because it is expected to only 
augment the natural pathways that release the endogenous CAR extracellular domain in 
the local environment. Given the limited amount of receptor, it is predicted to be non-
toxic and, since it is an endogenous pathway, is not expected be immunogenic.  
There are reports that ADAM17 is responsible for cleavage of many other viral 
receptors. For example, both CD163, a receptor for Porcine reproductive and respiratory 
syndrome virus (PRRSV) infection, and Angiotensin Converting Enzyme 2 (ACE2) a 
well-known receptor for severe acute respiratory syndrome (SARS) virus, have been 
shown to undergo shedding by ADAM17, an effect that leads to decreased entry of the 
corresponding virus (185, 186). Moreover, there is an argument that the efficiency of 
AdV entry depends on additional stepwise interactions with co-receptors, such as 
integrins (72, 73). As its names implies, (A Dis-integrins And Metalloprotease), 
ADAM17 may cause shedding of the integrins from the cell surface (95, 128) and, 
therefore, it is possible that this could be an additional mechanism to decreases the AdV 
transduction in airway epithelia.  
Although we have no preliminary data to indicate that AdV binding to CAREx8 
will initiate RIP, it will be very exciting if it does. First, it is well known that AdV 
infection can activate numerous cellular signaling and transcription pathways, many of 
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which remain unknown but could affect viral virulence (187, 188). Second, published 
evidence indicates that AdV and CVB bind CAR at the cell surface initially but that CAR 
does not enter cells with the virus (75, 189, 190). Finally, shedding of the CAR 
ectodomain could interfere with viral entry mechanism by endocytosis (75, 191). This 
would explain a longstanding gap in the field. Insights into any of these processes could 
enhance drug discovery for reduction of viral infection, and potentially even CAR-related 
diseases such as dilated cardiomyopathy (183). 
 PDZ3 binding peptides are basically the opposite of PDZ1 binding peptides. Blocking the 
interaction between MAGI-1 PDZ3 and CAREx8 led to increased CAREx8 interaction with 
the savior PDZ1 domain and rescued CAREx8 from degradation. My data suggests that 
this increase is associated with more CAREx8 initially co-localized with the nucleus but 
then with the various endosomes within the cells. It is possible that CAREx8 is simply 
escaping the MAGI-1 ERAD-like surveillance. Interestingly, MAGI-1 does not end up at 
the apical surface so there must be a step of release, potentially within the Golgi sorting 
steps or upon packing into endosomes. Although the pathway through the cell was not 
fully characterized, blocking only the PDZ3 domain with TAT-ESAM or blocking both 
PDZ1 and PDZ3 domains with TAT-CAREx8-9C appeared to be similar. Moreover, both 
of these peptides behaved similarly in vivo and increased AdV-Cre transduction of tdT 




In the future, we would like to test the protective effect of TAT-PDZ1 peptides in 
vivo against AdV infection using animal model of pathogenicity. We would also test the 
efficacy of TAT-PDZ1 peptides in protecting against the Coxsackievirus infection which 
also uses CAR for binding and entry. We will also test the effectiveness of TAT-PDZ3 
peptides in increase the AdV transduction and correction the cystic fibrosis in vitro and in 
vivo. Even though we did not detect any toxicity in our epithelia or in vivo, developing 
new peptides or other small molecule therapeutics with more specificity toward MAGI-1 
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